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I. INTRODUCTION 
Maternal diabetes is one of the most common metabolic disorders complicating 
pregnancy. Prevalence estimates in 2015 assumed that 20.9 million (16.2 %) of 129.4 
million live births were affected by hyperglycemia (IDF, 2015). Maternal diabetes can 
either result from preexisting type 1 or type 2 diabetes, or occurs during late pregnancy 
and hence is defined gestational diabetes mellitus (GDM) (ADA, 2016). Human 
epidemiological studies demonstrate that intra-uterine exposure to hyperglycemia, 
regardless of the type of maternal diabetes, has short- and long-term negative 
consequences for both the mother and the offspring (FETITA et al., 2006; FRASER 
& LAWLOR, 2014; MCCANCE, 2015). Even more alarming is the evidence from a 
large multicenter, multicultural, observational study involving 25.000 pregnant 
women, revealing that less severe degrees of hyperglycemia as such in overt diabetes 
mellitus are also associated with maternal/fetal and neonatal negative outcomes 
(GROUP et al., 2008).  
The impact of maternal diabetes on the offspring is extremely difficult to study in 
humans. Conversely, experimental animal models offer the possibility to investigate 
the consequences of maternal hyperglycemia and the underlying molecular 
mechanisms at different developmental stages. To date, animal models of maternal 
diabetes were mainly established in rodents (JAWERBAUM & WHITE, 2010; 
PASEK & GANNON, 2013), with considerable numbers using chemical diabetes 
induction with clear disadvantages. Only few models  represent clinically-relevant 
hyperglycemic levels (DAMASCENO et al., 2013) that are comparable to the tightly 
regulated glycemic control observed in pregnant diabetic women. Therefore, there is 
a need to develop clinically relevant experimental models of maternal diabetes. Pigs 
are an excellent and well-established animal model in diabetes research, closely 
resembling aspects of human glucose metabolism, including physiological metabolic 
alterations during pregnancy (PÈRE & ETIENNE, 2007; WOLF et al., 2014; 
RENNER et al., 2016a). 
The aim of present study was to first generate and characterize a novel genetically 
engineered porcine model of mild diabetes, characterize glucose control and insulin 
sensitivity of this model during the pregnant state and evaluate effects of in utero 
exposure to mild maternal hyperglycemia on the offspring.  
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II. REVIEW OF THE LITERATURE  
1. Metabolic and morphological adaptations during pregnancy 
in humans 
Metabolism encompasses complex networks of tightly regulated cellular processes 
that sustain a physiological balance in biological systems. Within these networks, 
maintenance of energy balance is a fundamental task that mainly involves i) 
maintenance of physiological glucose levels; ii) adequate insulin production and 
secretion; iii) adequate insulin response in peripheral insulin-sensitive tissues; and iv) 
maintenance of optimal glycogen and lipid storage to be catabolized at times of caloric 
restriction (BERG et al., 2007). Pregnancy is a transitional state that accounts for 
tremendous metabolic adaptations compared to the non-pregnant state. Those include 
changes in glucose metabolism, whole body insulin sensitivity, insulin secretion, lipid 
metabolism and, less studied, changes in protein metabolism (HADDEN & 
MCLAUGHLIN, 2009). In the context of pregnancy, glucose and energy metabolism 
are of particular relevance since the mother must meet the needs of a progressively 
increasing energy demand to allow a sufficient supply of nutrients for fetal 
development. In addition, these metabolic changes are critical to prepare the maternal 
organism for delivery and lactation as well as to provide adequate energy storages for 
the growing fetus upon birth (HADDEN & MCLAUGHLIN, 2009). In the first part of 
the literature review, the main metabolic changes in glucose and lipid metabolism that 
occur during normal pregnancy in humans will be described and compared to 
adaptations observed in large animal models, particularly in the pig. In the second part, 
pregnancy-associated metabolic changes in the context of a (pre-) diabetic state in 
humans and large animal models are in focus. 
 Changes in glucose metabolism  
Glucose homeostasis involves a network of metabolic processes that maintain 
circulating glucose levels within a physiological range. In humans, this range 
comprises fasting plasma glucose concentrations between 70 mg/dl to 90 mg/dl, in a 
physiological non-pregnant state (ADA, 2016). Maintenance of normoglycemia is 
therefore a balance between the rates of glucose entering the circulation and glucose 
disposal to peripheral tissues. Circulating plasma glucose is derived from external 
sources like nutrients absorbed through the small intestine, or from endogenous 
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sources such as the breakdown of glycogen stores via glycogenolysis as a primary 
energy source or by endogenous hepatic glucose production via gluconeogenesis, e.g. 
during longer fasting periods (GAGLIARDINO, 2005). Glucose removal from the 
blood stream is a strictly regulated process involving the key gluco-regulatory 
hormone insulin that stimulates glucose uptake into peripheral tissues and inhibits 
hepatic glucose production (DEFRONZO et al., 1983; DEFRONZO & 
FERRANNINI, 1987). In the fasting state, when glucose is only provided by 
endogenous sources (mainly by the liver), the rate of hepatic glucose production is 
equivalent to the rate of basal glucose-uptake. Thus, circulating glucose concentrations 
mainly reflect hepatic glucose production (DEFRONZO et al., 1989). Upon glucose 
load, plasma glucose levels increase and stimulate insulin secretion as well as insulin 
biosynthesis in the pancreas. Insulin inhibits hepatic glucose production and enhances 
glucose uptake in insulin sensitive tissues, mainly skeletal muscle, liver and fat 
(DEFRONZO et al., 1983; DEFRONZO & FERRANNINI, 1987).  
Generally, fasting glucose levels are decreased by 10 to 20 % in healthy pregnant 
women compared to healthy non-pregnant women (BLACKBURN, 2013). The lower 
glucose concentrations during pregnancy are attributed to dilution effects in volume 
distribution of glucose (KALHAN & ADAM, 1980), as well as to continuous 
increased demand in glucose utilization by the fetal-placental unit, especially during 
the last trimester (KALHAN et al., 1979; HADDEN & MCLAUGHLIN, 2009; 
ANGUEIRA et al., 2015). As to compensate fasting plasma glucose (FPG) decay 
endogenous glucose production is increased by 16 to 30 % in pregnant women with 
the progression of pregnancy (KALHAN et al., 1979; CATALANO et al., 1992; 
ASSEL et al., 1993), and gluconeogenesis is the preferred pathway contributing to 
glucose production during the fasting state in pregnant women (KALHAN et al., 
1997). Contrary to the fasting state, postprandial glucose levels during pregnancy are 
increased, and plasma glucose concentrations remain elevated for longer period 
following a meal, as compared to the non-pregnant state. Elevated postprandial 
glucose levels result from a minor impairment in glucose tolerance mainly due to 
changes in insulin sensitivity as explained below (DI CIANNI et al., 2003; HADDEN 
& MCLAUGHLIN, 2009; ANGUEIRA et al., 2015).  
 Insulin sensitivity  
In order to understand glucose homeostasis, primary physiological variables such as 
ß-cell response to glucose and tissue insulin sensitivity are pivotal parameters that can 
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be assessed by a variety of methods in diabetes research. The hyperinsulinemic-
euglycemic clamp (HIC) is the gold-standard method to determine in vivo insulin 
sensitivity (DEFRONZO et al., 1979). Contrary to the standard glucose and insulin 
stimulation tests (including oral and intravenous), where insulin sensitivity is mainly 
estimated through surrogated indexes, in the HIC, insulin sensitivity can be directly 
assessed by glucose infusion rate.  In a HIC setup, after an overnight fasting, insulin 
is infused at a constant rate, as to achieve a steady state of hyperinsulinemia. This 
suppresses endogenous production of insulin by ß-cells and glucose by the liver, as 
well as stimulates glucose uptake by peripheral tissues, mainly in skeletal muscle and 
adipose tissue. Simultaneously, glucose is infused at a variable rate, as to maintain a 
defined fasting plasma glucose concentration within the physiological range (also 
defined as euglycemic state). Therefore, the glucose amount infused throughout the 
steady state equals the glucose amount taken up by insulin-sensitive peripheral tissues. 
Consequently, the glucose infusion rate during steady state provides an absolute index 
of whole body insulin sensitivity. In insulin sensitive subjects, higher glucose infusion 
rates are required to maintain euglycemia as glucose is rapidly taken up and utilized 
by insulin sensitive tissues during the hyperinsulinemic condition. In contrast, in 
insulin resistant subjects, lower glucose infusion rates are necessary to maintain 
euglycemia as glucose uptake and utilization is reduced proportionally to the degree 
of insulin resistance in these subjects (DEFRONZO et al., 1979; MUNIYAPPA et al., 
2008; KIM, 2009). 
Studies using the hyperinsulinemic-euglycemic clamp have demonstrated that in the 
first 10-12 weeks of gestation insulin sensitivity is normal, compared to the non-
pregnant state (CATALANO et al., 1991; CATALANO et al., 1992). With progression 
of pregnancy, insulin sensitivity is reduced by 50 to 70 % in the third trimester in 
healthy pregnant women (RYAN et al., 1985; BUCHANAN et al., 1990; CATALANO 
et al., 1991; CATALANO et al., 1992; CATALANO et al., 1993; SIVAN et al., 1997). 
Reduced insulin sensitivity during pregnancy results from a marked reduction in 
insulin action in maternal peripheral tissues, especially in skeletal muscle and adipose 
tissue (BUTTE, 2000; DI CIANNI et al., 2003; HADDEN & MCLAUGHLIN, 2009; 
ANGUEIRA et al., 2015) and is the main event contributing to increased nutrient 
provision for the fetus (BUTTE, 2000; DI CIANNI et al., 2003). Although the 
molecular mechanisms underlying physiological insulin resistance in pregnancy are 
not completely understood, they involve impairment of insulin signaling to 
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downstream targets within the insulin signaling cascade (BARBOUR et al., 2007). 
Insulin-mediated glucose uptake is initiated by binding of insulin to the α-subunit of 
the insulin receptor tyrosine kinase (IR) in insulin-sensitive tissues. This induces a 
conformational change in the two subunits of the IR, resulting in autophosphorylation 
of several tyrosine kinase substrates in the IR. The active IR, subsequently 
phosphorylates downstream signaling molecules, including insulin-receptor substrate 
(IRS) proteins (IRS-1 and IRS-2 are important mediators in muscle and adipose 
tissue), which act as scaffolds to recruit and mediate signaling complexes (BOUCHER 
et al., 2014). Among them, recruitment of type 1A PI3-kinase (PI3K) is known to be 
directly involved in facilitating translocation of intracellular glucose receptors 
(GLUT) into the plasma membrane (BACKER et al., 1992; ALESSI & DOWNES, 
1998). Although the molecular mechanisms are not fully understood, it involves 
activation of AKT and subsequent phosphorylation cascade of PH-domain containing 
proteins including the serine/threonine protein kinase B (PKB)/AKT and the atypical 
protein kinase C (PKC) ζ isoform (PKCζ) that ultimately are recruited to the plasma 
membrane and facilitate intracellular-membrane-vesicles-containing GLUT receptors 
to translocate into the plasma cell membrane (BRYANT et al., 2002; ROWLAND et 
al., 2011). Reduced phosphorylation levels on the tyrosine kinase of IR, indicating IR 
impairment activity, were demonstrated in purified IR from skeletal muscle of 
pregnant women (SHAO et al., 2000). Moreover, IRS1 phosphorylation is reduced in 
muscle and liver of an experimental rat model of pregnancy, as well as in skeletal 
muscle of healthy pregnant women (DAMM et al., 1993; SAAD et al., 1997). In 
addition, reduced translocation of GLUT receptors has been identified. GLUT4 protein 
expression is significantly reduced in subcutaneous adipose tissue of healthy pregnant 
as compared to non-pregnant women (OKUNO et al., 1995). Friedman et al. 
demonstrated that insulin-induced GLUT4 translocation was reduced by 32 % in 
skeletal muscle of healthy pregnant women as compared to non-pregnant controls 
(FRIEDMAN et al., 1999). On the basis of understanding the underlying molecular 
mechanisms of insulin resistance, pregnancy-related endocrine changes have been 
intensively investigated (RYAN & ENNS, 1988; HANDWERGER & FREEMARK, 
2000; NEWBERN & FREEMARK, 2011). Progesterone has in vivo insulin 
desensitization effects particularly on hepatic glucose production in pregnant rats 
(NELSON et al., 1994). Plasma cortisol concentrations are greatly increased in human 
pregnancy (KIRWAN et al., 2002), and glucocorticoid treatment interfered with IR 
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signaling and IRS-1 expression in vivo in rats (GIORGINO et al., 1993). Lactogen 
hormones including human placental lactogen (hPL) and prolactin (PRL) stimulate 
maternal food intake by targeting in vivo leptin resistance in the rat brain 
(AUGUSTINE & GRATTAN, 2008). In addition, hPL stimulates in vitro insulin 
secretion in rat, mouse and human islets (BRELJE et al., 1993). Transgenic mice 
overexpressing human placental growth hormone (hPGH), demonstrated that hPGH 
enhances p85α subunit of PI3K which, in turn, impairs IRS1 and PI3K complex 
activity, thus blocking downstream insulin signaling in skeletal muscle 
(BANDYOPADHYAY et al., 2005; BARBOUR et al., 2005). In addition to 
pregnancy-associated hormones, others have investigated the role of adipose tissue-
specific cytokines, known as adipokines, and their contribution to insulin resistance. 
During pregnancy adipose tissue expansion takes place (CLAPP et al., 1988; ROJAS-
RODRIGUEZ et al., 2015) and adipokines like leptin, adiponectin and tumor necrosis 
factor alpha (TNF-α) have been implicated with increased insulin resistance in 
pregnancy (BARBOUR et al., 2007). Plasma leptin concentrations increase throughout 
gestation (BUTTE et al., 1997) and they correlate with maternal insulin and increase 
maternal fat mass (HIGHMAN et al., 1998; VIRKAMAKI et al., 1999). TNF-α is 
related with obesity-induced insulin resistance by inhibiting the activity of the IR 
(HOTAMISLIGIL et al., 1996) and so far is the only signaling factor that directly 
correlates with progressive changes in insulin sensitivity in vivo in humans (KIRWAN 
et al., 2002). The role of adiponectin as an insulin-sensitizing hormone in obese and 
type 2 diabetes patients is well described (ARITA et al., 1999; HOTTA et al., 2000; 
WEYER et al., 2001). Also, adiponectin levels were found reduced during the 3rd 
trimester of pregnancy compared to the non-gravid state, in agreement with reduced 
adiponectin mRNA expression in white adipose tissue of lean pregnant women 
(CATALANO et al., 2006). 
 Insulin secretion 
In addition to insulin sensitivity, β-cell function is the other pivotal variable impacting 
glucose metabolism. Glucose challenging tests are standard methods used to determine 
in vivo insulin secretion and therefore to assess ß-cell function and response. They are 
mainly performed with an oral or intravenous administration of a glucose bolus, and 
the effects of endogenous insulin secretion on systemic glucose clearance are 
evaluated based on frequently blood sampling (CERSOSIMO et al., 2014). 
Alternatively, ß-cell function can be assessed by the hyperglycemic clamp (HGC) test, 
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where ß-cell function is assessed under maximal stimulatory conditions (DEFRONZO 
et al., 1979). After an overnight fasting, plasma glucose concentration is acutely raised 
by intravenous infusion of glucose, and hyperglycemia is constantly held by 
continuous glucose infusion. To maintain the desired hyperglycemic plateau, the 
glucose infusion is adjusted based on frequent plasma glucose measurements. Because 
the plasma glucose concentration is held constant, the glucose infusion rate is a 
measure of insulin secretion capacity and β-cell function. Under this constant 
hyperglycemia setup, non-diabetic subjects reveal a biphasic pattern of plasma insulin 
response with a first phase insulin response (approximately the first 10 min) 
characterized by an early burst of insulin, followed by a gradually progressive increase 
in plasma insulin concentrations (second phase) (DEFRONZO et al., 1979; 
CERSOSIMO et al., 2014).  
Longitudinal studies on glucose tolerance upon intravenous glucose challenge indicate 
that insulin response is increased within the first weeks of pregnancy (12-14 week), 
achieving maximum levels during the third trimester, and returning to normal values 
after term (CATALANO et al., 1991; CATALANO et al., 1993). By the third 
trimester, both basal and postprandial insulin secretion levels are increased compared 
to non-pregnant state. This is accompanied by increased insulin secretion both in the 
1st phase (time 0 to 5 min.) and 2nd phase (from 5 until end test) (CATALANO et al., 
1991). Similarly, increased insulin response was observed during oral glucose 
tolerance tests in pregnant women, with a 120 % increased 1st phase insulin response 
during weeks 12-14 of gestation (BOWES et al., 1996). The capacity to compensate 
with increased insulin secretion during pregnancy is therefore an adaptive mechanism 
to maintain normoglycemia in pregnant women (BUTTE, 2000; DI CIANNI et al., 
2003). Despite development of insulin resistance in healthy pregnant women, glucose 
tolerance is only slightly reduced and associated with moderately elevated 
postprandial glucose levels (CATALANO et al., 1991; CATALANO et al., 1993; 
BOWES et al., 1996). These are essential to provide sufficient glucose to the fetus 
during interrupted periods of energy intake (BUTTE, 2000; DI CIANNI et al., 2003; 
ANGUEIRA et al., 2015). The inability to compensate the increased demand for 
insulin during pregnancy underlies the pathophysiological mechanisms of 
development of GDM (BUCHANAN et al., 2007). Hence, the insulin producing β-
cells must undergo several morphological and functional adaptions that are further 
discussed in 1.3. 
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 Changes in lipid metabolism  
Like glucose metabolism, lipid metabolism is also target of many physiological 
alterations during pregnancy. There is a great effort during the first two trimesters of 
pregnancy to promote accumulation of maternal lipid storages that can be later 
mobilized as energy source during the last trimester (BUTTE, 2000). Thus, 
morphological and functional changes occur at the level of adipocytes within the 
adipose tissue. There is an increase in adipose tissue expansion which is promoted by 
hypertrophy of fat cells (HERRERA, 2000; ROJAS-RODRIGUEZ et al., 2015). It is 
estimated that 3.3 kg of additional fat is stored within the first 15 weeks of normal, 
non-obese pregnancy (CLAPP et al., 1988). Concomitantly increased levels of 
pregnancy-related hormones and insulin are thought to facilitate the increased fat 
deposition in adipocytes by favoring lipogenesis and inhibiting lipolysis (HERRERA 
& DESOYE, 2016). In fact, the number of insulin receptors as well as insulin-mediated 
lipogenesis are increased in adipocytes in the first trimester of pregnancy (BAIRD, 
1986) which is then reduced by the development of insulin resistance (SIVAN et al., 
1999). Similar to glucose concentrations, circulating levels of triglycerides, non-
esterified fatty acids, cholesterol and phospholipids are reduced within the first eight 
weeks of pregnancy. Cholesterol is mainly canalized to the placenta for the synthesis 
of steroid hormones while fatty acids serve as building blocks e.g. for the synthesis of 
new cell membranes (BUTTE, 2000). Upon initial reduction, circulating lipid 
metabolites are found elevated following the first eight weeks of pregnancy. This is 
mainly due to increased lipid synthesis in the liver and reduced clearance of lipids from 
the circulation due to a decreased activity of lipases, particularly hepatic lipase 
(SATTAR et al., 1997). In parallel with increased levels of total cholesterol and 
triglycerides, levels of lipoproteins are also found elevated with progression of 
pregnancy and remain elevated until delivery (HERRERA & DESOYE, 2016). There 
is an overall increase in circulating high-density lipoproteins (HDL), low density 
lipoproteins (LDL), very low density lipoproteins (VLDL) and triacylglycerols 
(SATTAR et al., 1997; BUTTE, 2000). Elevation of the lipoprotein content is in line 
with increased levels of cholesterol ester transfer protein (CETP) found by several 
studies (SILLIMAN et al., 1993; IGLESIAS et al., 1994; ALVAREZ et al., 1996). 
CETP catalyzes the transfer of triglycerides in exchange of cholesterol esters to HDL 
and LDL lipoproteins.  
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In the 3rd trimester of pregnancy, where most of glucose is shuttled to the fetal-
placental unit to meet fetal energy demand, maternal metabolism relies on lipid content 
as a primary energy source. Thus, a switch from an anabolic state of building and 
storing lipid mass is replaced by a catabolic state of activation and utilization of the 
lipid reservoir (BUTTE, 2000; DI CIANNI et al., 2003). Hence, lipolysis and fat 
mobilization takes place, which is consistent with increased circulating free fatty acids 
(FFA), triglycerides and lipoproteins (HERRERA & DESOYE, 2016). Furthermore, 
in periods of prolonged (48 h) and shorter fasting (18 h), where most intermediates of 
carbohydrate metabolism are utilized for glucose production by gluconeogenesis, lipid 
oxidation is highly increased with accelerated production of ketone bodies. In fact, 
fatty acids and β-hydroxybutyrate products are increased in the circulation during 
fasting periods and are generated faster in pregnant women as compared to the non-
pregnant state (METZGER et al., 1980; METZGER, 1991).  
 Pancreas morphology, β-cell mass and mechanisms of β-cell adaptation 
to pregnancy  
During pregnancy, there is a continuous increase in insulin demand caused by the 
physiological endocrine-metabolic “insult” intrinsic to pregnancy. In order to respond 
to increased insulin secretion, the endocrine fraction of the pancreas is subject of major 
morphological and functional adaptions that contribute to enhanced insulin 
responsiveness. These major adaptions will be reviewed here mainly based on animal 
studies (especially mice) due to the obvious scarcity and heterogeneity among human 
samples.   
The pancreas is the organ mainly responsible for glucose homeostasis, since it 
produces the hormone insulin which is necessary to regulate circulating glucose levels. 
Insulin is produced exclusively by the β-cells, those comprising one out of five 
endocrine cell types in the pancreas (α-cells secrete glucagon; PP-cells secrete 
pancreatic polypeptide; δ-cells secrete somatostatin and ε-cells secrete ghrelin 
(MARICHAL, 2010). β-cells can either be organized in cell clusters of pancreatic 
islets or in small numbers of dispersed β-cells within the pancreas known as isolated 
β-cells (BOUWENS & PIPELEERS, 1998; DOLENŠEK et al., 2015). β-cells are the 
most abundant cell type within the islets (with exception for birds), however, with 
great differences in cell type proportion distribution and cytoarchitecture among 
species (KIM et al., 2009; STEINER et al., 2010). Human islets have reduced β-cell 
content (60 % β-cells) and increased α-content (30 % α-cells) as compared to 70 % β-
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cells and 20 % α-cells in murine islets, respectively (CABRERA et al., 2006). The 
cytoarchitecture of human islets is characterized by a heterogeneous β-cell 
distribution, while murine islets have a core of β-cells surrounded by the other cell 
types (BRISSOVA et al., 2005; CABRERA et al., 2006). Porcine islets resemble more 
human islets, where small β-cell clusters are scattered among the other endocrine cells 
types (CABRERA et al., 2006; STEINER et al., 2010).  
In order to compensate for the increased insulin demand due to reduced insulin 
sensitivity, the endocrine pancreas must enhance insulin synthesis and secretion 
capacity by expanding β-cell mass. It is known that β-cells can change in number 
(hyperplasia) and size (hypertrophy) during periods of increased insulin demand such 
as growth, pregnancy, or obesity (RIECK & KAESTNER, 2010). A great number of 
studies indicate that murine islets show a 3 to 4-fold increase in β-cell mass during 
pregnancy and proliferation of existing β-cells is the predominant underlying 
mechanism. (PARSONS et al., 1992; SORENSON & BRELJE, 1997; RIECK et al., 
2009; RETNAKARAN et al., 2016). Placental lactogens (SORENSON et al., 1993) 
and other regulatory hormones like serotonin (KIM et al., 2010) and menin (KARNIK 
et al., 2007) are involved in the regulation of β-cell mass during pregnancy in rodents. 
In humans, there is also evidence for an increased β-cell mass during pregnancy, 
although to a much smaller extent. Van Assche and co-workers reported a 2-fold 
increase in β-cell mass in five pregnant women (with an increase in number and size 
of β-cells) (VAN ASSCHE et al., 1978), whereas Butler et al. reported a smaller (1.4-
fold) increase in β-cell mass in 18 pregnant women around gestational week 25 
(BUTLER et al., 2010). The Butler study reported an increased number of small islets 
instead of enlargement of pre-existing islets with no changes in replication. Contrary 
to mice, where proliferation (PARSONS et al., 1992; RIECK et al., 2009) and 
hypertrophy (SORENSON & BRELJE, 1997; RIECK et al., 2009) of pre-existing 
islets were shown to be the preferential mechanisms of β-cell mass expansion, the data 
are contradictory in humans. The study by the Butler team shed light on the generation 
of new β-cells via neogenesis (generation of β-cells from non-differentiated 
precursors) since the increase in β-cell numbers resulted from newly formed islets as 
well as increase in insulin positive duct cells (BUTLER et al., 2010). In line with this 
finding a study conducted by Kou et al. on 72 pancreata obtained from autopsies of 
individuals without a history of pancreatitis or any type of diabetes (not involving 
pregnancy) observed that islet number rather than islet size was the main parameter 
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determining β-cell mass (KOU et al., 2014). Regulation of β-cell mass during 
pregnancy in the pig remains to be investigated.  
 Metabolic adaptions to pregnancy in large animal models with focus on 
the pig  
Experimental animal models that naturally depict the most common metabolic features 
of human pregnancy are of great value. They allow not only a comprehensive 
understanding of the physiological metabolic processes during pregnancy, but also the 
study of pregnancy complicated by metabolic disorders such as diabetes. Like humans, 
pigs use glucose as the major energy substrate for the fetus (FORD et al., 1984; PERE, 
1995, 2001). This is also true for other large animals like cows (FERRELL et al., 1983) 
and sheep (CHRISTENSON & PRIOR, 1978; MESCHIA et al., 1980). Blood samples, 
collected at the end of gestation revealed fetal glucose extractions of 0.3 mmol/L 
(PERE, 1995, 2001), 0.2 mmol/L (FOWDEN et al., 1997) and 0.32 mmol/L 
(COMLINE et al., 1979) in pigs. These values are comparable with fetal glucose 
extractions found in two human studies: 0.38 mmol/L (HOLME et al., 2015) and 0.34 
mmol/L (KUO, 1991), but lower than one report 0.6 mmol/L in humans (METZGER 
et al., 1985).  
Regarding fasting glucose levels during pregnancy in sows, most studies report no 
alterations in FPG between the pregnant and non-pregnant state (AHERNE et al., 
1969; REYNOLDS et al., 1985; DUEE et al., 1987; SIMOES NUNES et al., 1987; 
PÈRE et al., 2000; PÈRE & ETIENNE, 2007). Glucose-lowering effects of insulin, 
measured upon ingestion of a meal, were progressively reduced in primiparous sows, 
at mid pregnancy (59 days) and the end of pregnancy (106 days) resulting in 
significantly increased postprandial glucose levels, as compared to non-pregnant 
controls (PÈRE & ETIENNE, 2007). Pregnancy-related reduced glucose tolerance in 
primiparous sows is similar to observations in healthy pregnant women (KUHL, 1991; 
PIVA et al., 1991; HOMKO et al., 2001). Fasting insulin concentrations were reported 
to be unaltered in pregnant sows vs. non-pregnant controls (BOUILLON HAUSMAN, 
1986; SCHAEFER et al., 1991), while some studies observed decreased fasting insulin 
during pregnancy (SIMOES NUNES et al., 1987; PÈRE et al., 2000). Insulin 
sensitivity is also altered during pregnancy in pigs. Studies in pregnant sows at term, 
using hyperinsulinemic-euglycemic clamps (PÈRE & ETIENNE, 2007), oral glucose 
tolerance tests  (PÈRE & ETIENNE, 2007) and intravenous glucose tolerance tests 
(GEORGE et al., 1978; SCHAEFER et al., 1991; PÈRE & ETIENNE, 2007), 
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demonstrated that, like in humans, pigs showed a slight reduction in glucose tolerance 
(more pronounced at end of pregnancy), together with a decreased insulin sensitivity. 
In healthy pregnant women insulin resistance and elevated insulin secretion 
immediately return to the normal state postpartum (HOMKO et al., 2001; MAZAKI-
TOVI et al., 2011), whereas in pigs, insulin resistance and impaired glucose tolerance 
are still present throughout lactation and normalize after weaning (PÈRE & ETIENNE, 
2007). In fact, development of insulin resistance in pregnancy seems to be a conserved 
metabolic adaptation among species occurring not only in pigs, but also in sheep 
(DUEHLMEIER et al., 2013), goats (DEBRAS et al., 1989), dogs (CONNOLLY et 
al., 2004), rats (LETURQUE et al., 1984; LETURQUE et al., 1986; ROSSI et al., 
1993) and mice (MUSIAL et al., 2016). Of relevance, the degree of glucose tolerance 
in pregnant pigs can be influenced by the type of diet (VAN DER PEET-
SCHWERING et al., 2004; CORSON et al., 2008b; METGES et al., 2014). Sows fed 
from day 85 of gestation a standard diet containing non-starch polysaccharides 
supplemented with 164 g of fat (soybean oil) revealed increased body mass, back fat 
gain and decreased glucose tolerance during lactation as compared with pregnant 
controls fed a standard diet (VAN DER PEET-SCHWERING et al., 2004). In addition, 
Metges et al. demonstrated that pregnant sows (gestation day 84) fed a high 
protein/low carbohydrate diet were more insulin resistant compared with sows fed an 
isoenergetic low protein/ high carbohydrate diet and sows fed an isoenergetic standard 
diet. It was suggested that low carbohydrate fed sows, adapted to a dietary deficit in 
glucose by increasing insulin resistance, glucagon concentrations, decreasing glucose 
oxidation, and stimulating gluconeogenesis (METGES et al., 2014). Thus, diet 
supplementation in the pig during pregnancy can be used to manipulate maternal 
glucose metabolism towards an aggravated phenotype of impaired glucose tolerance, 
as seen in obese pregnant women (CATALANO et al., 1999).  
Similar to humans, increased lipid mobilization towards the end of pregnancy is also 
observed in pregnant sows which revealed elevated circulating FFA near term (day 
110) (PÈRE et al., 2000; PÈRE & ETIENNE, 2007). However, compared to humans, 
hyperlipidemia appears later in pigs, and is greater during the lactation period 
coinciding with the more pronounced insulin resistance phenotype (PÈRE & 
ETIENNE, 2007). Altogether, despite some differences, physiological metabolic 
adaptations to pregnancy in pigs resemble those in humans, making the pig a relevant 
animal model of human pregnancy that can be used to investigate molecular 
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mechanisms underlying pregnancy complicated by diabetes and its deleterious 
consequences for the offspring.  
2. Maternal diabetes: preconceptional and gestational diabetes 
mellitus 
 Definition, prevalence and diagnostic criteria  
Pregnancy is often defined as a transitory “diabetogenic” event (DI CIANNI et al., 
2003). This is due to its intrinsic physiological alterations in glucose-insulin 
metabolism which resemble complications seen in diabetes. However, contrary to the 
diabetic state, healthy pregnant women still maintain circulating glucose levels within 
physiological ranges that are defined by specific glycemic threshold values (BUTTE, 
2000; HADDEN & MCLAUGHLIN, 2009). Two forms of maternal diabetes are 
known: (1) preconceptional diabetes mellitus (PCDM) that includes pregnant women 
previously diagnosed either with type 1 or type 2 diabetes and (2) gestational diabetes 
mellitus (GDM), defined as “any degree of glucose intolerance with an onset or first 
recognition during pregnancy,” particularly arising around the 24th week of gestation 
(ADA, 2016). Both types of maternal diabetes are considered as a high-risk condition 
for the mother and the child. The International Diabetes Federation (IDF) reported that 
over the year 2015, 20.9 million (16.2 %) of 129.4 million live births (to women aged 
20-49 years) were affected by hyperglycemia. Of those, 85.1 % were due to GDM, 7.4 
% due to other types of diabetes first detected during pregnancy and 7.5 % due to 
diabetes detected prior to pregnancy (IDF, 2015). The prevalence of maternal diabetes 
is related to ethnicity, with the highest prevalence in South-East Asia (24 %), Middle 
East and North Africa (21.8 %), and much influenced by the socioeconomic status, 
with 87.6 % prevalence in low and middle income countries. In Europe the prevalence 
is 13.7 % with 1.7 million live births affected in 2015 (IDF, 2015).  
The same diagnostic criteria used to identify individuals in the population with 
diabetes (either type 1 or type 2) are applied to diagnose women with PCDM. Those 
consist of defined threshold values for specific diagnostic criteria. Thus, diabetes 
mellitus, is diagnosed when one of the following criteria is met: (1) FPG (with fasting 
being defined as non-caloric intake for a period of at least 8 h) ≥ 126 mg/dl, or (2) 
postprandial glucose (PG) levels two hours after a standardized oral glucose tolerance 
test (in humans a glucose load using 75 g anhydrous glucose dissolved in water) ≥ 200 
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mg/dl, or (3) glycated hemoglobin (HbA1c), a monitoring parameter of long-term 
blood glucose is ≥ 6.5 % (ADA, 2016).  
For decades there has been an extensive debate on defining clear cutoff criteria for 
GDM (HOUSHMAND et al., 2013; MCINTYRE et al., 2015). This was due to, 
heterogeneous criteria applied to define glucose tolerance in pregnancy (which 
initially focused primarily on maternal risk to develop type 2 diabetes rather than poor 
pregnancy outcomes), and second, to some uncertainty to which extent milder degrees 
of hyperglycemia during pregnancy impact maternal and neonatal outcomes. As a 
result of the current epidemic rise in obesity that has led to more cases of women in 
childbearing age with undiagnosed type 2 diabetes (LAWRENCE et al., 2008), it 
became mandatory to redefine GDM criteria. Furthermore, a large multinational 
cohort study, the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, 
was performed to clarify the impact of minor degrees of hyperglycemia (FPG 75 to 
100 mg/dL; 1h PG 106-212 mg/dL; 2h PG 90-178 mg/dL) during pregnancy on 
maternal/offspring adverse outcomes (GROUP et al., 2008). The study was conducted 
on a large group of 25.000 pregnant women undergoing a 75-g oral glucose tolerance 
test at 24-28 weeks of gestation. From this study, a continuous association between 
the degree of maternal glycemia and the risk of adverse maternal, fetal and neonatal 
outcomes was demonstrated (GROUP et al., 2008). Importantly, the risk association 
of maternal hyperglycemia with adverse neonatal outcomes was reported in maternal 
glycemia degrees less severe than overt diabetes mellitus (GROUP et al., 2008), and 
was independent of maternal obesity (which in combination with GDM aggravated the 
risk for deleterious outcomes) (CATALANO et al., 2012). Taking these considerations 
into account, the American Diabetes Association (ADA) redefined the diagnostic 
criteria for GDM as follows. If women at their initial prenatal visit present risk factors 
for type 2 diabetes, (those including Body Mass Index (BMI) ≥ 25 kg/m2 with 
additional risk factors like physical inactivity, family history of diabetes, high risk 
race/ethnicity, hypertension ≥ 140/90 mmHg or undergoing hypertension therapy, 
HDL cholesterol levels < 35 mg/dL and/or triglyceride levels ≥ 250 mg/dL, history of 
cardiovascular diseases, polycystic syndrome, HbA1c levels ≥ 5.7 %, or any other 
clinical condition associated with insulin resistance previously diagnosed) they should 
be tested for diabetes mellitus using the standard diagnostic criteria. If diabetes is 
confirmed during the 1st trimester, women should be classified with type 2 diabetes. If 
women do not present any of the risk factors above, they should be diagnosed for GDM 
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within weeks 24-28 of gestation (ADA, 2016). However, as a result of the HAPO 
study, the GDM diagnostic criteria differ and are stricter as compared to the standard 
type 1 and 2 criteria. Thus, GDM diagnostic criteria can be accomplished following 
either a one-step or a two-step screening approach. A one-step approach involves 
performing a 75-g oral glucose tolerance test within weeks 24-28 of gestation with 
samples collected at fasting, 1-h and 2-h following the glucose load. Women are 
diagnosed with GDM when any of the following parameters are met: FPG ≥ 92 mg/dL, 
or 1-h PG ≥ 180 mg/dL or 2-h PG ≥ 153 mg/dL (threshold values defined according 
to the International Association of the Diabetes Pregnancy Study Groups) 
(INTERNATIONAL ASSOCIATION OF et al., 2010; ADA, 2016). In a two-step 
approach, step one consists of a 50 g glucose load test (non-fasting), with plasma 
measurements at 1-h post glucose load. If plasma glucose levels are ≥ 140 mg/dL, they 
proceed to step two with a 100 g oral glucose tolerance test (OGTT) (plasma 
measurements at fasting, 1-h, 2-h and 3-h after OGTT). The diagnosis of GDM is 
confirmed if at least two of the following parameters are met: FPG ≥ 95 mg/dL, 1-h 
PG ≥ 180 mg/dL, 2-h PG ≥ 155 mg/dl and 3-h PG ≥ 140 mg/dL (threshold values 
defined by Carpenter/Coustand) (CARPENTER & COUSTAN, 1982; ADA, 2016) or 
FPG ≥ 105 mg/dL, 1-h PG ≥ 190 mg/dL, 2-h PG ≥ 165 mg/dl and 3-h PG ≥ 145 mg/dL 
(threshold values defined by the National Diabetes Data Groups) (GROUP, 1979; 
ADA, 2016). The decision for the one-step or two-step procedure is of debate 
(VANDORSTEN et al., 2013). The one-step procedure using the threshold criteria 
from the IADPSG has been adopted internationally and therefore, it is the preferential 
approach (DURAN et al., 2014). Nevertheless, it has been under discussion, since 
these criteria raise the prevalence of women diagnosed with GDM, and it is not yet 
clear if this results in an overestimation of the number GDM cases with need for 
medical intervention and costs (VANDORSTEN et al., 2013). The two-step approach 
is the preferential route in the US which has updated its guidelines in 2013 by The 
American College of Obstetricians and Gynecologists (COMMITTEE ON 
PRACTICE, 2013). Long-term outcome studies using both approaches are needed and 
are currently ongoing to commit to an internationally applicable diagnostic regimen 
(ADA, 2016). 
 Consequences of maternal diabetes  
Human epidemiological and experimental animal studies demonstrate that intra-
uterine exposure to hyperglycemia, regardless of which type of maternal diabetes, has 
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short- and long-term negative consequences for both the mother and the offspring 
(FETITA et al., 2006; FRASER & LAWLOR, 2014; MCCANCE, 2015). Thus, 
maintenance of normoglycemia in pregnancy is imperative for reducing adverse 
maternal, fetal and neonatal outcomes. In PCDM, the onset of diabetes is prior to 
gestation and therefore, poorly maternal glycemic control (especially within the 1st 
trimester) has great impact on early embryonic development (ORNOY et al., 2015). A 
systematic meta-analysis review, involving 14.099 women with type 1 diabetes and 
4.035.373 women from background population revealed a 2-to 5-fold increased risk 
for the development of congenital malformations, perinatal mortality, preterm delivery 
and large for gestational age births in women with type 1 diabetes (COLSTRUP et al., 
2013). Moreover, despite generally milder glycemic impairment in women with type 
2 compared with type 1 diabetes, both diabetes types showed poor pregnancy 
outcomes in a systematic meta-analysis (BALSELLS et al., 2009). In fact, women with 
type 2 diabetes showed higher risk of perinatal mortality compared to type 1 diabetic 
women and were not significantly different from type 1 women in rates of congenital 
malformations, stillbirth and neonatal mortality (BALSELLS et al., 2009). In the case 
of GDM, the rate of fetal congenital malformations is not increased compared with 
normal pregnancy (SCHAEFER et al., 1997; FARRELL et al., 2002). Nevertheless, 
despite lower impairment in glucose control compared to type 1 and type 2 diabetic 
women, several deleterious consequences for both mother and offspring are known. 
Macrosomia, defined as weight at birth >4.000 g (LUBCHENCO, 1970; KC et al., 
2015), occurs in 30 % of the neonates of diabetic mothers (UVENA-CELEBREZZE 
& CATALANO, 2000) and a linear relationship between this outcome and the degree 
of maternal hyperglycemia has been supported by different studies, including 
pregnancies complicated by GDM (HILL et al., 2005; YOGEV et al., 2005; GROUP 
et al., 2008). Macrosomia is usually accompanied by disproportional growth of 
shoulders and abdomen in comparison to the head, thus contributing to serious 
obstetric complications such as bone injuries, shoulder dystocia, increased emergency 
cesarean section and assisted deliveries (KC et al., 2015). As a result of an intrauterine 
hyperglycemic environment, fetal hyperinsulinemia was long hypothesized 
(PEDERSEN, 1954) and is in line with findings of elevated cord blood C-peptide 
levels in GDM offspring (GROUP et al., 2008) and increased insulin levels in the 
amniotic fluid of both PCDM and GDM fetuses (SILVERMAN et al., 1995). 
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In addition to deleterious neonatal outcomes, both PCDM and GDM have an impact 
beyond the perinatal period. Studies with Pima Indians, a population with the highest 
prevalence of type 2 diabetes (KNOWLER et al., 1978), were the first to demonstrate 
an increased incidence of type 2 diabetes in the offspring as a consequence of exposure 
to a hyperglycemic intrauterine environment (DABELEA et al., 2000; LINDSAY et 
al., 2000). In the Pima Indian population, offspring of diabetic mothers had an 
increased incidence of type 2 diabetes compared to the offspring of type 2 diabetic 
fathers (LINDSAY et al., 2000). Another study conducted in siblings of Pima Indians, 
in which one of the siblings was born before maternal development of type 2 diabetes, 
revealed 45 % higher incidence of diabetes in the offspring whose mothers were 
diabetic during pregnancy as compared to 9% incidence for those siblings where the 
mother became diabetic after pregnancy (DABELEA et al., 2000). Because the Pima 
Indian population is particular in terms of small genetic variability (WILLIAMS et al., 
1992) and since the development of type 2 diabetes has partially a genetic contribution 
(MORRIS et al., 2012), the impact of hyperglycemia in utero could still be argued. 
Using individuals from populations with higher genetic variability, increased 
impairment of glucose tolerance and reduced insulin secretion was demonstrated in 
adult offspring from type 1 diabetic mothers (without any presence of islet-
autoantibodies of type 1 diabetes) as compared to offspring of diabetic type 1 fathers 
(SOBNGWI et al., 2003). Like in PCDM, offspring of GDM mothers also have a 
greater risk to develop metabolic complications during childhood and adult life. A 
follow-up study in offspring (age 18-27) of GDM, revealed reduced insulin sensitivity, 
β-cell function and glucose tolerance compared with the offspring of background 
population (KELSTRUP et al., 2013). Moreover, the prevalence of IGT and type 2 
diabetes in offspring (age 18-27) of diet-treated GDM mothers was 26 % compared 
with 4 % in the offspring from the background population (CLAUSEN et al., 2008). 
Earlier reports also support an increased prevalence of IGT (CLAUSEN et al., 2009), 
or of IGT and type 2 diabetes (SILVERMAN et al., 1995; PLAGEMANN et al., 1997) 
in offspring of GDM mothers.    
 Animals models of maternal diabetes  
Diabetes in pregnancy results in an unfavorable hyperglycemic intrauterine 
environment for the growing fetus, thus supporting the onset of maternal, fetal, 
neonatal and perinatal complications. With the current epidemic rise in obesity in both 
economically favorable and unfavorable countries, and the increased number of 
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women developing GDM and type 2 diabetes it is imperative to understand the 
pathophysiological consequences of maternal hyperglycemia and to develop 
appropriate disease prevention/treatment strategies. Due to obvious ethical reasons, 
human studies, don´t allow to fully explore the molecular mechanisms underlying 
maternal diabetes and poor offspring outcomes. Therefore, animal models, in 
particular large animal models, are of great value as they can bridge the gap between 
rodent models and humans (WOLF et al., 2014; RENNER et al., 2016a). Different 
methods can be applied to induce hyperglycemia prior/during pregnancy, and 
according to the onset, they intended to mimic PDCM (hyperglycemia before or during 
early pregnancy with either features of type 1 or type 2 diabetes) or GDM 
(hyperglycemia in late phase of pregnancy with mild maternal glycemia) 
(JAWERBAUM & WHITE, 2010; PASEK & GANNON, 2013). Pancreatectomy was 
the first method used to induce maternal diabetes. This method involves partial or total 
removal of the pancreas by surgery, resulting in corresponding degrees of diabetes. As 
a highly invasive procedure, it generates a high degree of inflammation with high post-
surgical mortality rates and is therefore not commonly used anymore (PASEK & 
GANNON, 2013). More recently, other methods such as chemical targeted ablation of 
β-cells (either with streptozotocin or alloxan), diet-induced diabetes and genetically 
engineered animal models became preferential strategies. Chemically induced 
maternal diabetes is described in multiple species including rats, mice, rabbits, sheep 
and pigs (JAWERBAUM & WHITE, 2010; PASEK & GANNON, 2013). This 
strategy has been extensively used with dose administrations either before pregnancy 
or right after mating in rodents as to evaluate congenital malformations potentially 
induced by hyperglycemia (SIMAN et al., 2000; HIGA et al., 2007; MORGAN et al., 
2008; SUGIMURA et al., 2009). In addition, dose titration of these compounds, type 
and route of administration, animal strain and age are all variables that play a role in 
inducing either mild maternal hyperglycemia (FPG levels within 117 – 176 mg/dl) or 
severely maternal hyperglycemia (FPG levels > 200-360 mg/dl) during pregnancy 
(DAMASCENO et al., 2013). Rodent studies using chemically-induced-mild-maternal 
diabetes resulted in β-cell hyperplasia, increased pancreatic insulin content and 
elevated in vivo insulin secretion in fetuses evaluated at term (KERVRAN et al., 1978; 
BIHOREAU et al., 1986a). However, adult animals exposed to mild maternal 
hyperglycemia were glucose intolerant due to a reduced glucose-induced insulin 
secretion (BIHOREAU et al., 1986b; AERTS et al., 1988; GAUGUIER et al., 1991). 
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Distinct effects were observed in neonates from chemically-induced severe maternal 
hyperglycemia. In these animals, although β-cell mass was increased, the islets 
contained few insulin granules suggesting insulin secretion exhaustion (AERTS et al., 
1990) In adulthood, β-cells were hyperactive and secreted more insulin however, 
insulin sensitivity was reduced (AERTS et al., 1990). In a study of chemically-induced 
maternal diabetes in pigs, hyperglycemia in the late phase of pregnancy impacted the 
energy status of the offspring. Piglets born to diabetic sows showed increased liver 
weight together with increased liver protein content as well as higher glycogen and 
lipid content. No differences were reported for litter size and birth weights of the 
piglets (EZEKWE et al., 1984). Chemical induction of maternal diabetes has been 
widely used, particularly in mice, and these experiments reflected important proof of 
principle studies in which impaired maternal glucose metabolism may be transmitted 
to the offspring by exposure to hyperglycemia in utero. Nevertheless, it is a very 
artificial method in which the natural etiology of the disease is omitted and side effects 
with cytotoxicity in other organs cannot be excluded (LENZEN, 2008).  
Genetic engineering of important genes involved in glucose metabolism is a strategy 
that has generated a great number of diabetic animal models (type 1 and 2), particularly 
in rodents. However, only a small number of studies used this strategy in the context 
of maternal diabetes and until present, all these studies were performed in rodents. 
Genetically engineered strains like the non-obese diabetic (NOD) mice (KOLB, 1987) 
and Akita mouse (YOSHIOKA et al., 1997) are examples of type 1-like diabetes 
models, hence being used to investigate consequences of PCDM in the offspring. 
Wild-type embryos transferred into diabetic NOD mice show an increased rate of 
congenital embryo malformations and oocytes of diabetic NOD mice show a higher 
number of chromosomal abnormalities (OTANI et al., 1991). Macrosomia and 
increased insulin content have been reported in the offspring of NOD mice (FORMBY 
et al., 1987). Wild-type offspring born to Akita mice show metabolic alterations 
including reduced glucose tolerance, decreased body weight (BW) and bone mineral 
density, and those alterations are more pronounced in male offspring (GRASEMANN 
et al., 2012). Other mouse models were generated by targeting genes which play 
important roles in β-cell expansion during pregnancy. Those include the global 
heterozygous prolactin receptor deficient mice (Prlr+/-) (HUANG et al., 2009), the 
conditional knockout c-Met in the pancreas (PancMet KO) (DEMIRCI et al., 2012), 
the global conditional serotonin receptor knockout (Htr2b-/-) mice (KIM et al., 2010), 
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the conditionally overexpressed menin in β-cells (βMen1) (KARNIK et al., 2007) and 
the depleted Forkhead box D3 (FOXD3) transcriptional factor (Foxd3fl/-) mice 
(PLANK et al., 2011). These animals maintain normal glucose levels before pregnancy 
and β-cell mass is preserved (with exception for the Prlr+/- and Foxd3fl/- mice in which 
β-cell mass deterioration occurs already before pregnancy). With progression of 
pregnancy, β-cell expansion as a compensatory mechanism is impaired, so the animals 
render diabetic during pregnancy. Although these models have contributed to a better 
understanding of the role of specific factors and signaling pathways in β-cell expansion 
in murine pregnancy, most have not explored consequences of maternal diabetes in 
offspring. A recent study using a mouse model of maternal insulin resistance that 
develops transient hyperglycemia during pregnancy due to a liver-specific knockout 
of the insulin-receptor (LIRKO mouse model), showed metabolic alterations in the 
wild-type offspring of diabetic mothers during post-natal life. Those included low birth 
weight followed by rapid weight gain. Plasma concentrations of glucose and insulin 
were increased. In addition, the offspring developed alterations in β-cell mass and 
increased fat deposition as shown by an increase in adipocyte size (KAHRAMAN et 
al., 2014).  
Finally, nutrition manipulation can be used to alter maternal metabolism during 
pregnancy. In humans, obesity is a well described risk factor of type 2 diabetes and 
GDM (DABELEA & CRUME, 2011). In the context of maternal diabetes, nutrition 
manipulation has been extensively used in rodent models, and to a smaller extent in 
large animal models, to describe the impact of environmental factors on metabolic 
changes in the offspring and the development of type 2 diabetes later in life 
(WILLIAMS et al., 2014). In mice, high fat diet (HFD) has been shown to impair 
maternal food intake, body composition, glucose and lipid metabolism, leptin 
concentrations and placental nutrient transport (WILLIAMS et al., 2014). In the 
offspring, HFD leads to hypertension, insulin resistance, dyslipidemia and hepatic 
steatosis and even the “transmission” to type 2 diabetes in later offspring generations 
as well as behavioral and mental changes (WILLIAMS et al., 2014). Dietary 
interventions using HFD have also been used in large animal models. HFD before and 
throughout pregnancy in ewes induced maternal insulin resistance and increased 
plasma glucose levels at mid gestation (FORD et al., 2009). Offspring from these 
pregnancies were evaluated at fetal stage (75 days of gestation) and exhibited 
increased pancreas weight and β-cell mass with increased β-cell proliferation (FORD 
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et al., 2009). Another study with diet-induced obesity in sheep reported early placental 
inflammation with changes in fetal lipid metabolism like increased circulating fatty 
acids, triglycerides and cholesterol (ZHU et al., 2010). Due to their value in the food 
chain, dietary studies were performed in sows during pregnancy as to improve piglet 
birth performance and to optimize the natural variance in birth weights in piglets 
within the same litter (ANDERSON et al., 1971; AVERETTE et al., 1999). A study 
using diet supplementation with different oil types during gestation in sows 
demonstrated larger birth weights, when the diet was supplemented with palm oil or 
olive oil (LAWS et al., 2007). Using the same oil supplementation principle, Corson 
et al. showed that maternal glucose tolerance is decreased upon HFD-feeding during 
gestation, however these effects were seen only in the group feed in the first half of 
gestation (CORSON et al., 2008b). Reduced glucose tolerance as a consequence of 
HFD-feeding was also observed by others (VAN DER PEET-SCHWERING et al., 
2004). 
In summary, different approaches in different animal species have been used to induce 
diabetes prior to/during pregnancy proving that experimental animals are valid and 
valuable tools to understand the mechanisms by which maternal hyperglycemia 
modulates fetal metabolism and perpetuates metabolic dysfunctions in the offspring. 
Nevertheless, the majority of the understanding comes from rodent studies, which 
cannot be directly translated into human patients. The pig is an excellent and well-
established model in diabetes research, as several aspects of the human glucose 
metabolism, including physiological alterations in pregnancy are depicted in pigs 
(GEORGE et al., 1978; PERE, 1995; FOWDEN et al., 1997; PÈRE & ETIENNE, 
2007; WOLF et al., 2014). In addition, for evaluating the impact of maternal 
hyperglycemia at a phenotypical and molecular level in the offspring, pigs become a 
much more suitable model compared to mice. Not only the fetal developmental stages 
in pigs resemble more the developmental stages in humans, the last fetal 
developmental stage (which accounts for period of great maternal metabolic changes 
impacting the fetus), occurs in utero in both pigs and humans, whereas this phase 
occurs postnatally in mice (LITTEN-BROWN et al., 2010).   
 
The aim of present study was to first generate and characterize a novel genetically 
engineered porcine model of mild diabetes, characterize glucose control and insulin 
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sensitivity of this model during the pregnant state and evaluate effects of in utero 
exposure to mild maternal hyperglycemia on the offspring.  
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III. ANIMALS, MATERIAL AND METHODS  
1. Animals 
Animals included in this study were hemizygous transgenic pigs expressing the mutant 
insulin C93S as well as age-matched non-transgenic controls on a German Landrace-
Swabian Hall background. In most cases littermate controls were used. During the 
whole study pigs were housed under controlled conditions in planar pens covered with 
straw, had ad libitum access to water and were fed a commercial diet Table 1. All 
animal experiments were approved by the responsible animal welfare authority 
(Regierung von Oberbayern, AZ 55.2-1-54-2531-26-06 and 55.2-1-54-2532-68-11). 
Table 1: Diet composition 
 Piglets up to 25 kg Juvenile and adult pigs 
MJ ME/kg 14.6 13.8 
Crude protein % 21.7 21.5 
Crude fat % 3.2 3.3 
Crude ash % 6.3 6.6 
Crude fiber % 5.6 7.4 
Calcium % 9.2 8.0 
Phosphorus % 5.8 5.4 
Sodium % 2.4 1.8 
Magnesium % 3.1 2.4 
ME: metabolized energy 
2. Materials  
 Chemicals 
Acetic Acid (glacial) Roth, Karlsruhe 
Agarose UltraPureTM Invitrogen, Karlsruhe 
Braunol® B. Braun, Melsungen 
Bromophenol Blue Roth, Karlsruhe  
1.4-Dithiothreitol (DTT) Biomol GmbH, Hamburg 
EDTA (Ethylenediaminetetraacetic acid) Roth, Karlsruhe and VWR, 
Darmstadt 
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Ethanol Roth, Karlsruhe 
Ethidium bromide (1mg/ dL) Merck, Darmstadt 
Glycerin (Glycerol) Roth, Karlsruhe 
Glucosteril® 50% Glucose solution  Fresenius Kabi, Standort 
Neufahrn 
H2O2 (Hydrogen peroxide) Roth, Karlsruhe 
HCl (Hydrochloric acid) VWR, Darmstadt 
Histokitt Glaswarenfabrik Karl Hecht 
MgCl2 (Magnesium chloride) Fluka Chemie, Schweiz 
Mayer‘s Hemalum solution Merck, Darmstadt 
Na3C6H5O7 (Sodium citrate) Merck, Darmstadt 
NaCl (Sodium chloride) Merck, Darmstadt 
Na2HPO4 (Di-sodiumhydrogenphosphate-2-
hydrate) 
Merck, Darmstadt 
NaOH  (Sodium hydroxide) Roth, Karlsruhe and VWR, 
Darmstadt 
Roti-Histofix 4 % Roth, Karlsruhe 
Sodium chloride solution (0.9%) B. Braun, Melsungen 
Tris (Tris-(hydroxymethyl) aminomethane) Roth, Karlsruhe 
Xylene  Applichem GmbH, Darmstadt 
 Consumables 
Adhesive tape  Tesa SE, Hamburg 
Adhesive tissue tape Henry Schein® Vet GmbH, 
Hamburg 
Aluminium spray CP – Pharma, Burgdorf 
Careflow® 3 Fr, 200 mm   Argon Medical Devices, USA 
Catheter stopper with injection cap Fresenius Kabi, Standort 
Neufahrn 
CBAS® Heparin Coated Clear PU Cath 7Fr Access Technologies, USA 
Combitips® plus (2.5 mL, 10 mL) Eppendorf, Hamburg 
Cover slips (24x40 mm) VWR International GmbH, 
Darmstadt 
Discofix® multi-way cock system B. Braun, Melsungen 
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Discofix® 3-way stop-cock with connection 
line (10 cm) 
B. Braun, Melsungen 
Disposable syringes (2, 5, 10, 20 mL) Henry Schein® Vet GmbH, 
Hamburg 
Gauze pads (7.5 cm x 7.5 cm) Hartmann, Austria 
Neolus® hypodermic needles (30 G) Terumo, Eschborn 
Falcon® centrifuge tubes (15, 50 mL) Becton Dickinson, Heidelberg 
Fixomull stretch BSN medical GmbH, Hamburg  
FreeStyle Precision® glucose stripes                      Abbott, USA 
Hypodermic needles (18 G, 20 G) Henry Schein® Vet GmbH, 
Hamburg 
Monovette® blood collection system  
(Plasma, EDTA, 9 mL) 
Sarstedt, Nümbrecht  
 
Nylon membrane (Nylon-N+)  GE Healthcare, UK 
OP-Cover (60 x 90 cm) A. Albrecht, Aulendorf 
Original Perfusor® Line (50cm) B. Braun, Melsungen 
Original Perfusor® syringes (50 mL) B. Braun, Melsungen 
Parafilm® M American Can Company, USA 
PCR reaction tubes (0.2 mL)  Braun, Wertheim 
Pipette tips with filter Axygen Inc., USA 
SafeGrip® latex gloves SLG, Munich 
Scalpel blade sterile No.36  Medicon eG, Tuttlingen 
Sempermed® supreme latex OP gloves Sempermed, USA 
Sephadex G-50 columns GE Healthcare limited, Munich 
Skin adhesive spray  A. Albrecht, Aulendorf 
Star Frost® microscope slides Engelbrecht, Edermünde 
3-way-stopcock Variostop® Clinico GmbH, Bad Hersfeld 
Surgibond tissue glue (SMI) SMI AG, Belgium 
Surgicryl® suture material  
(USP 2-0 without needle) 
SMI AG, Belgium 
Surgicryl suture  
(USP 2/0 with needle DS30) 
SMI AG, Belgium 
Surgicryl suture  
(USP 2/0 with needle DS36) 
SMI AG, Belgium 
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Test tube peg wrack Polylab, India 
Uni-Link embedding cassettes Engelbrecht, Edermünde 
 Devices 
Agarose gel electrophoresis chamber OWL Inc., USA 
ART-Micra D-8 tissue-homogenizer ART, Müllheim 
AU 480 analyzer Beckman & Coulter, USA 
Benchtop 96 tube working rack Stratagene, USA 
BX41 light microscope Olympus, Hamburg 
DP72 video camera Olympus, Hamburg 
FreeStyle Precision® neo glucometer Abbott, USA 
Gel documentation system Bio Rad, Munich 
Genome Analyzer IIx, Illumina® Illumina®, USA 
HemoCue® Glucose 201+ Glucometer Radiometer GmbH, Willich 
Hybrid mini 38 hybridisation oven H. Saur, Reutlingen 
HM 315 microtome Microm, Walldorf 
Injectomat® MC Agilia, infusion pumps Fresenius Kabi, Bad Homburg 
Incubator 37 °C Wagner + Munz, Munich 
Incubator 60 °C Memmert, Schwabach 
inoLab® pH meter 7110 WTW, Weilheim 
LB 2111 γ-counter Berthold, Bad Wildbad 
Object micrometer Zeiss, Oberkochen 
Mastercycler® gradient Eppendorf, Hamburg 
Microwave DAEWOO, Korea 
Multichannel pipette mLine® (300 µl)                     Sartorius, USA 
Multipipette® plus Eppendorf, Hamburg 
NanoDrop ND-1000 spectrophotometer  NanoDrop Technologies, USA 
Pipettes (1000 µl, 200 µl, 100 µl, 10 µl, 2 µl) Gilson Inc., USA 
Power Pac 300 gel electrophoresis unit Bio Rad, Munich 
RH Basic heating plate with magnetic stirrer IKA, Staufen 
Shandon Citadel tissue processor 1000 Thermo Fisher Scientific, 
Schwerte 
Select vortexer Select BioProducts, USA 
Sony video graphic printer UP-895CE Sony, USA 
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TBS 88 tissue embedding system Medite, Burgdorf 
Tecan infinite M200Pro ELISA reader Tecan, Swizerland 
Thermomixer 5436 Eppendorf, Hamburg 
WB 6 water bath Preiss-Daimler Group, Puschwitz 
X-ray cassette Rego, Augsburg 
 
Centrifuges:  
Eppendorf Centrifuge 5430 R Eppendorf, Hamburg 
Eppendorf Centrifuge 5810 R Eppendorf, Hamburg 
Heraeus Sepatech Megafuge 1.0R Heraeus, Munich 
Rotanta 460R  Hettich, Tuttlingen 
 
Scales:  
Analytic balance Sartorius, Göttingen 
Analytic balance MS 100 Schippers GmbH, Kerken 
Kern EOB 15K5, animal balance Kern und Sohn GmbH, Barlingen-
Frommern 
 Antibodies and drugs  
 Antibodies 
Polyclonal guinea pig anti-porcine insulin Dako Cytomation, Hamburg 
AP-conjugated goat anti-guinea pig IgG Southern Biotech, USA 
 Drugs 
Altrenogest (Regumate®) Serumwerke Bernburg, Bernburg 
Azaperon (Stresnil®) Jansen Pharmaceutica, Belgium 
Cefquinom (Cobactan® 2.5%) Intervet, Unterschleißheim 
Choriongonadotropine (hCG) (Ovogest®) Intervet, Unterschleißheim 
Cloprostenol (Estrumate-Schwein®) Intervet, Unterschleißheim 
Embutramid, Mebezoniumiodid, 
Tetracainhydrochlorid (T61®) 
Intervet, Unterschleißheim 
Insulin (Insuman® rapid) Sanofi-Aventis Deutschland 
GmbH, Frankfurt 
Isobar® Isoflurane Intervet, Unterschleißheim 
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Ketamine hydrochloride (Ursotamin®) Serumwerke Bernburg, Bernburg 
Leukase® N Kegel Dermapharm AG 
Meloxicam (Metacam®) Boehringer Ingelheim, Ingelheim 
Pregnant Mare Serum Gonadotropin (PMSG) 
(Intergonan®) 
Intervet, Unterschleißheim 
TaurolockTM Hep 500, Catheter lock solution TauroPharm GmbH, Winsen 
Xylazine 2 % WDT, Garbsen 
 Buffers and solutions 
DNA loading buffer (10×): 
10 % glycerol in distilled water 
1 spatula tip of Bromophenol Blue 
0.5 M NaOH until color turns blue 
Aliquoted and stored at 4 °C 
 
dNTP-mix: 
2 mM dATP, dCTP, dGTP, dTTP 
Mixed in distilled water 
Aliquoted and stored at -20 °C 
 
Southern blot church buffer: 
1% BSA 
1 mM EDTA, pH 8.0 
500 mM sodium-phosphate buffer pH 7.2 
7% SDS 
 
Southern blot high stringency buffer: 
1 mM EDTA, pH 8.0 
40 mM sodium-phosphate buffer pH 7.2 
1% SDS 
 
Southern blot low stringency buffer: 
0.5% BSA 
1 mM EDTA 
40 mM sodium-phosphate buffer pH 7.2 
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5% SDS 
Southern blot neutralisation solution: 
0.5 M Tris 
1.5 M NaCl 
pH 7.5 
 
Southern blot strand break solution: 
0.5 M NaOH 
1.5 M NaCl 
 
Southern blot 20x SSC: 
0.3 M Na-Citrate 
3 M NaCl 
 
TAE buffer (50×): 
242 g 2 M Tris 
100 mL 0.5 M EDTA (pH 8.0) 
57 mL glacial acetic acid 
1000 mL distilled water 
Filtrated and autoclaved for storage 
Before usage diluted to single concentration 
 
TBS buffer: 
90 g NaCl 
60.5 g Tris 
1000 mL distilled water 
pH adjusted to 7.6, autoclaved and diluted to single concentration before use 
 
100 mM Tris HCl (pH 8.5): 
12.114 g Tris 
1000 mL distilled water 
pH adjusted to 8.5, autoclaved  
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 Kits 
QiaexII Gel Extraction kit  Qiagen, Hilden 
Porcine C-peptide ELISA kit                                     Mercodia, Sweden 
NexttecTM Genomic DNA Isolation Kit Nexttec GmbH, Leverkusen 
Porcine Insulin RIA Kit Millipore, USA 
RNeasy® Mini total RNA isolation Kit  Qiagen, Hilden 
Vector® Red Substrate Kit (AP) Biozol, Eching 
Wizard genomic DNA purification Kit®  Promega, USA 
 Other reagents  
BamHI restriction enzyme Fermentas, St. Leon Roth 
Bovine serum albumin (BSA)  Roth, Karlsruhe 
DNA labeling α-[32P]-dCTP PerkinElmer, Netherlands 
DNase I, RNase-free (1 U/µL) Thermo Scientific, Schwerten 
dNTPs (dATP, dCTP, dGTP, dATP) MBI Fermentas, St. Leon Roth 
Gene RulerTM (1 kb DNA ladder) MBI Fermentas, St. Leon Roth 
Goat serum MP Biomedicals, France 
Klenow fragment exo- (5 U/µL) Fermentas, St. Leon Roth 
Lambda DNA EcoRI + HindIII Fermentas, St. Leon Roth 
10 x PCR buffer Qiagen GmbH, Hilden 
Pig serum MP Biomedicals, France 
SuperScript® III Reverse Transcriptase (200 
U/µL) 
Thermo Scientific, Schwerten 
Taq DNA Polymerase (5 U/mL) Agrobiogen, Hilgertshausen 
 Software 
Graph Pad Prism® version 5.02 GraphPad Software Inc., USA 
MagellanTM data analysis version 7.2 Tecan, Swizerland 
Olympus VisiomorphTM image analysis Visiopharm, Denmark 
LBIS immunoassay software version 3.3.0.0 Berthold Technologies GmbH, 
Bad Wildbad 
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3. Methods  
 Generation of INSC93S transgenic pigs  
 Expression construct, SCNT and embryo transfer 
INSC93S transgenic pigs were generated by additive gene transfer into somatic cells 
followed by somatic cell nuclear transfer (SCNT) and embryo transfer. The expression 
vector designed by Dr. Nikolai Klymiuk and Dr. Christina Landbrecht-Schessl (Chair 
for Molecular Animal Breeding and Biotechnology, LMU Munich) consists of three 
major fragments: a 1.3-kb fragment of the porcine insulin promoter, a 1.0-kb fragment 
of the porcine full-length insulin gene sequence including the three exons and a 
neomycin resistance cassette (Figure 1). In exon 3 of the insulin gene, a TA point 
mutation at nucleotide position 336 was inserted, leading to an amino acid exchange 
from cysteine to serine at position 93 in the amino acid sequence of the insulin protein 
and subsequently a loss of an intra-insulin-A-chain disulfide bond. The porcine insulin 
(INS) promoter is active exclusively in the β-cells of the pancreas (GRZECH et al., 
2010). The expression vector was transfected into male porcine fetal fibroblasts of 
both the German Landrace and the Swabian-Hall pig breed. Selection of positive cell 
clones was performed in a G418 containing culture medium. Pools of stable 
transfected cell clones were used for SCNT using in vitro maturated oocytes as 
described in (KUROME et al., 2015). Briefly, a single donor cell was inserted into the 
perivitelline space of an enucleated oocyte, followed by fusion with electrical pulses. 
After culturing (1 to 2 days), the cloned embryos were transferred laparoscopically 
into the oviduct of estrus-synchronized surrogate gilts. In total, 503 cloned embryos 
were transferred into five recipients, of which two went to full term. Cell culture 
experiments were executed by Dr. Annegret Wünsch, SCNT and embryo transfer 
experiments were performed by Dr. Mayuko Kurome and Dr. Barbara Kessler (Chair 
for Molecular Animal Breeding and Biotechnology, LMU Munich).  
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 Identification of INSC93S transgenic animals  
Both polymerase chain reaction (PCR) and Southern blot analyses were used to 
identify INSC93S transgenic animals. In addition, Southern blot analysis allowed to 
determine the number of integration sites of the INSC93S transgene in the F0-generation 
and possible segregation events in the F1-generation. 
 Polymerase chain reaction (PCR) 
3.2.1.1. Genomic DNA isolation from tails  
Tail punches were obtained and stored at -20 °C. Genomic DNA was isolated using 
the “nexttecTM Genomic DNA Isolation Kit from Tissue and Cells” (nexttec GmbH, 
Leverkusen) according to the manufacturer’s instructions. Briefly, samples were cut 
in small pieces of a diameter < 1 mm and were incubated with an appropriate lysis 
buffer. Samples were incubated overnight at 60°C in a thermomixer. Lysates were then 
purified using nexttecTM clean columns to elute purified DNA. 
3.2.1.2. PCR reaction 
Previous purified DNA was amplified in a PCR reaction. The following specific 
primers directed to the sequence of the neomycin resistance cassette were used to 
differentiate between transgenic and non-transgenic pigs:  
 
Figure 1: INSC93S expression construct 
The insulin gene (1.0-kb) is flanked by the porcine insulin promoter (1.3-kb) and 
the removable neomycin resistance cassette. Within the insulin gene fragment, 
boxes represent exons whereas connective lines between boxes represent introns. 
Unfilled boxes depict coding sequence regions (cds) whereas filled boxes represent 
untranslated regions (UTR) on the message RNA sequence. In the last exon the 
point mutation at nucleotide position 366 is indicated. 
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NeoP(f):   5´-CTG TGC TCG ACG TTG TCA C-3´ 
NeoS(r):   5´-GAA GAA CTC GTC AAG AAG GCG ATA G-3´ 
 
In addition, a control PCR using ß-actin (ACTB) was run in parallel with the same 
samples as loading and DNA integrity control. ACTB specific primers are listed 
below:  
 
ACTB (f):  5´-TGG ACT TCG AGC AGA GAT GG-3´ 
ACTB (r):  5´-CAC CGT GTT GGC GTA GAG G-3´ 
 
PCR components were mixed on ice to a final volume of 25 µL in 0.2 mL reaction 
tubes. Genomic DNA from wildtype (WT) pigs served as control and distilled water 
was used as a non-template control. Details for master mix ingredients and PCR 
conditions are listed in Table 2 and Table 3. 
Table 2: Master mix components per PCR reaction 
Master Mix components INSC93S  
µL 
ACTB 
µL 
10× PCR buffer 2.5 2.5 
MgCl2 (15 mM) 2.5 2.5 
dNTPs (2 mM) 5 5 
Primer (f) (10 µM) 0.4 0.5 
Primer (r)(10 µM) 0.4 0.5 
Taq Polymerase (5 U/µL) 0.2 0.2 
Aqua dest. 13 12.8 
DNA template 1 1 
Table 3: PCR reaction conditions for both INSC93S and ACTB 
Denaturation 95 °C 4 min.  
Denaturation 95 °C 30 sec.   
Annealing 62 °C 30 sec.  35x 
Elongation 72 °C 30 sec.   
Final elongation 72 °C 5 min.  
Termination 4 °C 5 min.  
3.2.1.3. Agarose gel electrophoresis 
An agarose gel electrophoresis was run to visualize the final PCR products. Therefore, 
a 2 % agarose gel was prepared by heating 1 × TAE buffer with 1 g/100 mL universal 
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agarose in the microwave. After cooling down to about 55 °C, ethidium bromide was 
added to the mixture in a concentration of 0.5 µg/mL and the gel was decanted into an 
electrophoresis chamber (OWL Inc., USA) for polymerization. 
 
Samples were mixed with 2.5 µL 10× DNA loading buffer and pipetted individually 
into the slot chambers of the gel. Six µL of Gene RulerTM 1 kb DNA molecular weight 
marker (MBI Fermentas) was included for the determination of DNA fragment sizes. 
An electric field with a voltage of 130 V was applied so that DNA samples migrate 
according to their size. After separation DNA samples were visualized under 
ultraviolet (UV) light. 
 Southern blot  
3.2.2.1. Isolation of genomic DNA from ear punches 
Tissue was obtained from ear punches and genomic DNA was isolated with the Wizard 
genomic DNA purification Kit® (Promega) according to the manufacturer’s 
instructions. Briefly, tissue pieces of 3-5 mm were lysed overnight by incubation at 
55°C in a thermomixer. After overnight digestion, stepwise purification was 
performed to remove larger non-digestible components, RNA and proteins. Purified 
samples were mixed with isopropanol for DNA precipitation. DNA was washed with 
70 % ethanol, air-dried and reconstituted with rehydration solution. Genomic DNA 
concentrations were measured using a NanoDrop ND-1000 (NanoDrop Technologies) 
spectrophotometer.  
3.2.2.2. Restriction enzyme digestion and gel electrophoresis 
Genomic DNA was digested into smaller fragments by overnight incubation at 37°C 
with the restriction enzyme BamH1 (MBI Fermentas). Fragments were loaded into a 
1 % agarose gel and separated by electrophoresis as described in 3.2.1.3. Following 
electrophoresis, the gel was treated with 0.3M hydrochloric acid for 45 min. to further 
digest larger fragments (larger than 15 kb) and subsequently incubated with a DNA 
double-strand break solution for 45 min. Thereafter, the gel was incubated with 
neutralization solution for 20 min. Finally, genomic DNA was transferred to a positive 
loaded Nylon membrane (Nylon-N+, GE Healthcare) by capillary transfer for 24 
hours. After the transfer the membrane was soaked with neutralization solution for 5 
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min. and air-dried. Transferred DNA was cross-linked to the membrane by UV-light 
irradiation at a dose of 120 J/cm2. Then the membrane was stored at room temperature. 
3.2.2.3. Radioactive labeling of the probe  
A specific probe to the neomycin resistance cassette of the INSC93S expression vector 
was generated for detection of the integrated INSC93S transgene. Probes were amplified 
by PCR using the same transgene-specific primers and protocol as described in 3.2.1.2. 
Plasmid DNA containing the INSC93S construct served as template. After 
electrophoresis, bands were removed from the gel and the amplified probe DNA was 
eluted with QiaexII Gel Extraction kit (Qiagen) according to manufacturer’s 
instructions. The DNA concentration was estimated by comparison of DNA band 
intensity to the band intensity of the known molecular weight standard Lambda DNA 
EcoRI + HindIII (MBI Fermentas) on an agarose gel. Probes were radioactively 
labeled with α-[32P]-dCTP (Perkin-Elmer, Netherlands), using a fragment of 
Polymerase I (Klenow exo-), which integrates radiolabeled nucleotides. Next, probes 
were denatured at 97 °C for 10 min. and directly placed on ice. Subsequently, single 
strand DNA probes were hybridized in a mixture with random primers (3 g/l), an 
appropriate buffer, a 0.33 M mix of dTTs, α-[32P]-dCTP (3000 Ci/mmol) and distilled 
water for 1 hour at 37 °C. Unincorporated nucleotides were removed by centrifugation 
through Sephadex G-50 columns. Finally, radioactive labeled probes were denaturized 
at 97°C for five min. a second time and stored on ice.  
3.2.2.4. Hybridization and signal detection 
Previously, blotted Hybond-N+ Nylon membranes were pre-wetted with 5 x SSC and 
pre-hybridized in 30 mL of Southern blot church buffer for one hour at 58°C in a 
hybridization oven. Previously labelled probes were diluted with Southern blot church 
buffer and were allowed to hybridize to the nylon membranes overnight at 58°C under 
permanent rotation in the hybridization oven. After hybridization washing steps were 
performed as follows: 2 x with low-stringency buffer at room temperature and 2 x with 
high-stringency buffer at 58°C. For signal detection, membranes were exposed to X-
ray films in an X-ray cassette for at least 24 hours at -80°C. X-ray films were 
developed in developing and fixing solutions according to the manufacturer’s protocol 
and subsequently analyzed.  
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 Quantification of expression levels of the endogenous and mutant 
insulin by next generation sequencing 
Expression levels of INS and INSC93S transcripts in pancreas samples from five founder 
boars and from F1 offspring of founder boars 9748 and 9776 respectively were 
quantified by next generation sequencing of RT-PCR products as described in 
(RENNER et al., 2013).  
3.2.3.1. RNA isolation from pancreas 
Total RNA was extracted from pancreatic tissue using RNeasy® Mini total RNA 
isolation Kit (Qiagen) according to the manufacturer´s instructions. Briefly, frozen 
pancreatic tissue (30-50 mg) was homogenized with recommended buffer using an 
ART-Micra D-8 tissue-homogenizer (23,500 rpm). Lysates were centrifuged (3 min., 
14,000 rpm, 4°C) and supernatants were mixed 1:1 with ethanol (70%). Total RNA 
was eluted with clean-up columns in 50 μl RNase-free water. After RNA elution, RNA 
concentration was measured using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies). RNA quality was evaluated by agarose gel electrophoresis. 
3.2.3.2. DNaseI digest and reverse transcription 
Purified RNA was digested with DNaseI to eliminate possible contaminants of 
genomic DNA. Therefore, 800 ng of total RNA from each sample were incubated 
together with DNaseI (10 U/µl) at a final concentration of 1 U/µl and an appropriate 
lysis buffer for 30 min. at 37°C on a thermomixer. DNaseI was inactivated by 
incubation at 75°C for ten min. followed by cooling down on ice for several min. Ten 
µl DNaseI digested RNA were reverse transcribed using random hexamer primers and 
SuperScriptTM II Reverse Transcriptase (Invitrogen) according to the manufacturer’s 
instructions. Complementary DNA was stored at -20 °C until further processing.  
3.2.3.3. PCR  
Complementary DNA (cDNA) samples were then amplified by PCR. Table 4 and 
Table 5 indicate the used PCR reagents and PCR reaction conditions respectively.  
The following primers were used for cDNA amplification of insulin (INS):  
Insulin(f):   5´-CGGGAGGCGGAGAACCCTCA-3‘ 
Insulin (r):  5‘-CCCTCAGGGGCGGCCTAGTT-3‘ 
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Table 4 Master mix components per PCR reaction 
Master Mix components Insulin  
µL 
10× PCR buffer (Qiagen) 2 
MgCl2 (25 mM) (Qiagen) 1.25 
Q-solution (Qiagen) 4 
dNTPs (2 mM) 2 
Primer (f)(10 µM) 0.4 
Primer (r) (10 µM) 0.4 
Taq Polymerase (5 U/µL) 8.75 
Distilled water 1 
cDNA template 1 
Table 5: PCR reaction conditions for INS. 
Denaturation 95 °C 4 min  
Denaturation 95 °C 30 sec   
Annealing 62 °C 30 sec  35x 
Elongation 72 °C 45 sec   
Final elongation 72 °C 10 min  
Termination    
 
Agarose gel electrophoresis was performed as described in 3.2.1.3.  
3.2.3.4. Next generation sequencing 
Next generation sequencing was used to determine the expression level of the mutant 
insulin C93S and endogenous insulin transcripts respectively using an Illumina 
Genome Analyzer IIx (>10,000 reads per sample). Next generation sequencing 
analysis was performed by Dr. Stefan Krebs, Laboratory of Functional Genome 
Analysis, Gene Center, LMU Munich. 
 Phenotypic characterization of INSC93S transgenic pigs before 
pregnancy 
After generation and genotypic characterization, the metabolic phenotype of INSC93S 
transgenic animals was further characterized. Fasting and non-fasting plasma glucose 
levels, and glucose tolerance was investigated in five INSC93S founder boars. From 
those, founders 9776 and 9748, with the most pronounced phenotype, were chosen for 
further investigations and were bred to wild-type sows. Data of F1 offspring of founder 
9776 is presented while results of F1 offspring of founder 9748 are only mentioned in 
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the text. BW gain, (fasting) glucose concentrations, glucose tolerance and insulin 
secretion as well as total β-cell volume were evaluated. The phenotype of offspring 
from founder 9776 was followed until the F4 generation as well as during pregnancy.   
 Body weight (BW) gain and (fasting) blood glucose levels (FBG) 
BW was recorded using a standard large animal scale when animals were 57, 72, 153 
and 175 days of age.  
For determination of (non-)fasting blood glucose levels, a blood drop was taken from 
a superficial ear vein using a blood lancet. Samples were directly measured with a 
FreeStyle Precision® neo glucometer. Blood glucose was regularly evaluated in all 
founder boars from 15 to 207 days of age.  
 Metabolic tests 
To assess in vivo glucose clearance and therefore, investigate glucose tolerance and 
insulin secretion, mixed meal glucose tolerance tests (MMGTT) and intravenous 
glucose tolerance tests (IVGTT) were performed in INSC93S transgenic pigs and non-
transgenic littermates at four and seven months of age.  
3.3.2.1. Surgical implantation of marginal ear vein catheters 
Three days prior to the glucose challenge marginal ear vein catheters were placed 
under general anesthesia. This assured stress-free, frequent blood sampling in 
unrestrained animals during the tests. Anesthesia was induced by intramuscular 
injection of azaperone (2 mg / kg BW) and ketamine hydrochloride (20 mg / kg BW) 
and maintained by ketamine (20 mg / kg BW) and xylazine (0.05 mg / kg BW). Under 
anesthesia, animals were positioned in dorsal recumbence and the internal and external 
area of the ear was shaved, washed with soap and finally aseptically prepared using a 
7.5% povidon-iodide containing solution (Braunol®) and an alcohol-based disinfectant 
(Kodan®). A marginal ear vein was punctured with a cannula (Figure 2: Catheter 
placement into a marginal ear vein 
(A) Ear vein punctured with cannula, (B) Guide wire insertion, (C) Skin expansion 
with dilatator, (D) Catheter placement, (E) Blood collection and (F) Catheter suture.  
A) followed by straight insertion of a guide wire through the cannula ~ 20 cm upstream 
into the vein (Figure 2 B). Subsequently, the needle was gently removed without 
pulling the wire. A dilator was placed over the wire and was pushed forward several 
millimeters to expand the skin opening and facilitate the insertion of the catheter 1 mm 
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in diameter (Figure 2 C). The dilator was removed and the catheter (Careflow® 3 Fr, 
200 mm) was inserted over the wire into the vein (Figure 2 D). Once the catheter was 
fully inserted the guide wire was removed. To assess proper function of the catheter a 
blood sample was withdrawn using a 2 mL syringe. (Figure 2 E). An inject stopper 
was placed to lock the catheter followed by catheter flushing with 0.9% NaCl. The 
catheter was fixed to the ear with one suture and secured with adhesive tape (Figure 2 
F). Finally, the catheter was filled with TauroLock® solution containing heparin to 
preserve its patency. Catheter placement was performed by Dr. Simone Renner and 
Dr. Istvan Novak (Chair for Molecular Animal Breeding and Biotechnology, LMU 
Munich).  
 
 
 
3.3.2.2. Mixed meal oral glucose tolerance test (MMGTT) 
Six days prior to the metabolic tests animals were housed in individual pens with straw 
bedding and free access to water. During the adaption period animals were normally 
fed with standard pig food according to age and BW. One day prior to the MMGTT 
BWs were recorded using a standard large animal scale. Animals were fasted for 18 
hours prior to the MMGTT. A mixed meal-glucose mixture was prepared by mixing 
50% glucose (2 g/kg BW) with commercial pig food (90 g for 4-month-old and 400 g 
for 7-month-old animals). Extension tubes (50 cm) were connected to the catheters 
Figure 2: Catheter placement into a marginal ear vein 
(A) Ear vein punctured with cannula, (B) Guide wire insertion, (C) Skin expansion 
with dilatator, (D) Catheter placement, (E) Blood collection and (F) Catheter suture. 
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and secured on the back of the pigs with one stripe of tape. The mixed meal was given 
at the time point zero and the time until the meal was fully eaten was recorded. Blood 
samples were taken at -10, 0, 15, 30, 45, 60, 90 and 120 min. relative to meal 
administration and processed as described in 3.3.3. Also, pig behavior was recorded 
throughout the test.  
3.3.2.3. Intravenous glucose tolerance test (IVGTT) 
For IVGTTs the same standard housing conditions were applied as previously 
described in 3.3.2.2. Animals were fasted for 18 hours prior to the test. At time point 
0, a glucose bolus (0.5 g/kg BW) was injected into the ear vein catheter within the 
minimum time possible and the injection duration was recorded. Immediately 
afterwards, the catheter was flushed with 20 mL of 0.9% isotonic NaCl solution. Blood 
samples were collected at time points -10, 0, 1, 3, 5, 7, 10, 15, 20, 30, 40, 50, 60 and 
90 min. relative to the glucose load. Samples were processed as described in 3.3.3. 
Throughout the test the pig behavior was recorded.  
 Sample processing  
Immediately after collection in nine mL plasma EDTA collection tubes, samples were 
placed on ice, centrifuged (1,500 x g for 15 min. at 4°C) and stored at -80°C for further 
analyses. 
3.3.3.1. Determination of plasma glucose concentrations by spectrophotometry 
Glucose was analyzed with an automated analyzer (Beckman & Coulter AU480 
Analyzer). Optical density was measured with a photometric lamp. Determination of 
plasma glucose was performed by Dr. Birgit Rathkolb, Helmholtz Zentrum Muenchen.  
3.3.3.2. Determinations of plasma insulin concentration by radioimmunoassay 
(RIA)  
Insulin concentrations were assessed using a porcine insulin RIA kit (Millipore) 
according to the manufacturer’s instructions. In this assay a fixed concentration of 125I-
labeled insulin is mixed with an unknown concentration of unlabeled insulin present 
in the porcine plasma samples. Both substrates compete for a constant but limited 
concentration of binding sites of anti-insulin antibodies. Subsequently, the antibody-
bound tracer is separated from the unbound radioactive tracer by precipitation. The 
antibody-bound fraction is measured in a γ-counter. Insulin concentrations of unknown 
samples were calculated with LBIS immunoassay software (version 3.3.0.0). All 
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samples were measured in duplicates and only values with a coefficient of variance 
(CV) less than 10% were accepted. The detection limit of this assay is 1.611 µU/mL.  
 Quantitative-stereological analyses of the pancreas    
Quantitative stereological analyses of the pancreas were performed to investigate 
differences in volume density and total volume of β-cell between INSC93S transgenic 
pigs and non-transgenic littermate controls.  
3.3.4.1. Pancreas preparation and random systematic sampling  
Pancreata from F1 offspring of founder 9776 were collected at an age of 13 months 
(388.57 19.5 days). Following euthanasia, the entire pancreas was explanted. Then 
connective tissue was removed and the pancreas was weighed. The pancreatic ring was 
cut between the lobus pancreatis sinister and the connective lobe and brought into a 
straight position. For subsampling the length of the pancreas was determined and tissue 
slices (thickness 0.5 cm) were cut out every 2.5 cm over the whole length of the organ, 
tilted to the left side and prefixed in 4% neutral buffered formalin for 8 hours. Then 
tissue samples were selected according to a random systematic sampling procedure as 
described in (ALBL et al., 2016). Briefly, tissue slices were covered by a 1 cm2 point-
counting grid. All points of the counting grid hitting pancreatic tissue were marked, 
counted and their sum was divided by 20 and defined the quotient Y. Then a random 
number X between one and quotient Y was chosen. Finally, tissue samples of about 1 
cm2 at position X, X+Y, X+2*Y, X+3*Y until X+20*Y were selected, placed in 
embedding cassettes and routinely processed with a tissue processor (Shandon Citadel 
tissue processor 1000). Following paraffin embedding with the TBS 88 Paraffin 
Embedding System, sections of 3 µm thickness were cut with a HM 315 microtome, 
mounted on 3-aminopropyltriethoxysilane-treated glass slides and placed in an 
incubator at 37 °C to dry until immunohistochemical staining. 
3.3.4.2. Immunohistochemical staining of insulin-positive cells 
The immunohistochemistry technique was used to stain insulin-positive cells. 
Pancreatic tissue sections were deparaffinized in xylene for 15 min. and rehydrated in 
gradually decreasing alcohol concentrations (99%, 96%, 70% alcohol and distilled 
water). The indirect alkaline phosphatase (AP) immunohistochemistry method was 
used. The individual steps of the protocol are indicated in Table 6. Finally, slides were 
dehydrated in gradually increasing alcohol concentrations (distilled water, 70%, 96%, 
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99% alcohol), cleared in xylene and mounted with cover slips using the quick-
hardening mounting medium histokitt.  
Table 6: Immunohistochemistry staining protocol for insulin 
 Protocol step Purpose Incubation 
time  
1. Hydrogen peroxide (1%) Blocking of endogenous 
peroxidase  
15 min 
2. TBS buffer Washing 10 min 
3. Goat serum 1:10 in TBS  Blocking unspecific binding 30 min 
4. Primary antibody (Polyclonal 
guinea pig anti-porcine insulin) 
1:1000 in TBS  
Primary antibody  60 min 
5. TBS buffer Washing 10 min 
6. Secondary antibody (AP-
conjugated goat anti-guinea pig 
IgG) 1:100 in TBS + 5 % porcine 
serum  
Secondary antibody 60 min 
7. TBS buffer Washing 10 min 
8. Vector® Red chromogen diluted in 
100 mM Tris HCl (pH 8.5) 
Color reaction 20 min 
9. Distilled water Washing 5 sec 
10. Mayer´s hemalum solution  Counterstaining  10 min 
11. Running tap water Washing  5 min 
3.3.4.3. Quantitative stereological analyses  
Volume density of -cells in the pancreas and total -cell volume was determined 
using the computer-assisted Olympus VisiomorphTM image analysis system with the 
NEWCast software coupled to a light microscope (Olympus, BX41) and a color video 
camera (Olympus DP72). With the 20x objective selected (total magnification 200x), 
an automated-random-image-sampling of 50 % of the total tissue area in each slide 
was performed. For each image generated, the software automatically recognized red-
stained insulin positive cells and blue-stained pancreatic tissue and attributed a 
numeric score per region identified. Thus, total -cell area A(β-cell,50%) and total area of 
pancreatic tissue A(Pan,50%) was calculated from the sum of all scores. From these areas, 
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the volume density of -cells in the pancreas (Vv(β-cell/Pan)) was determined by dividing 
the total β-cell by the total pancreas area [Vv(β-cell/Pan) = A(β-cell,50%) /A(Pan,50%)]. The total 
β-cell volume V(β-cell,Pan) was then calculated by multiplying Vv(β-cell/Pan) with the total 
pancreas volume (V (Pan)). V(Pan) is defined by the quotient of the pancreas weight and 
the specific weight of the pig pancreas (sp. W. (Pan)= 1.07 g/cm3). The specific weight 
of the pig pancreas was determined by the submersion method as previously described 
(Scherle 1970). 
 Phenotypic characterization of INSC93S transgenic sows and wild-type 
littermates during pregnancy 
Effects of the expression of the mutant insulin C93S were investigated during 
pregnancy in pregnant INSC93S transgenic sows (INSC93S-p) and pregnant wild-type 
sows (wt-p) and these animals were named ‘study group’ in the following chapters. 
As a control group for physiological adaptations during pregnancy in wt sows non-
pregnant wt sows (wt-np) were included.  
 Reproduction management of sows 
3.4.1.1. Estrus synchronization and artificial insemination 
Wild-type (n=9) and INSC93S transgenic sows (n=3) aged 9 ± 0.84 months were estrus 
synchronized by a 16-day once daily oral application of Altrenogest (Regumate®, 20 
mg/animal per day). Ovulation was induced 48 hours after the last Regumate® 
administration by a single intramuscular injection of Pregnant Mare Serum 
Gonadotropin (Intergonan®; 750 I.U. per animal) followed by a single intramuscular 
injection of Choriongonadotropin (Ovogest®, 750 I.U. per animal) 76 hours later. 
Twenty-four and 48 hours after Ovogest® injection, sows were artificially inseminated 
with semen from the same wt boar. Pregnancy was confirmed by ultrasonography 21 
days after insemination. Sows were group-housed until 107 of pregnancy.    
3.4.1.2. Birth induction  
At day 107 of pregnancy sows were placed in individual maternity pens for adaption. 
On day 112 of pregnancy birth was induced by a single intramuscular injection of 
cloprostenol (Estrumate®, 0.175 mg per animal). Farrowing took place between 24 to 
36 hours after birth induction.  
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 Fasting blood glucose levels throughout gestation 
To assess effects of pregnancy on fasting glucose homeostasis, blood glucose levels 
were measured between gestational weeks three and sixteen in regular intervals. Four 
wt-p and three INSC93S-p sows as well as four wt-np and three INSC93S-np sows were 
included in the measurements. Following an 18-hour fasting period blood was 
collected and blood glucose measured as described in 3.3.3.1 
 Glucose clamps 
Two types of glucose clamps, the hyperinsulinemic-euglycemic clamp (HIC) and the 
hyperglycemic clamp (HGC), were performed during pregnancy. Hence in vivo insulin 
sensitivity and β-cell function were characterized. Sows included in the HIC and HGC 
were 13 ± 0.15 months of age. The HIC and HGC were performed at gestational week 
80 ± 2.30 gestational week 86 ± 2.82 respectively. 
3.4.3.1. Surgical implantation of arterial and central venous catheters  
At gestational day 71 ± 2.5 catheters were inserted into the carotic artery and external 
jugular vein under general anesthesia.  
Anesthesia was induced by intramuscular injection of azaperone (2 mg / kg BW) and 
ketamine hydrochloride (20 mg / kg BW) and maintained by inhalation of 1% 
isoflurane. Peri-surgical analgesia was provided by an intravenous injection of 
Metamizol (50 mg per kg BW). Under anesthesia, animals were positioned in dorsal 
recumbence and the jugular groove was shaved, washed with soap and finally 
aseptically prepared using a 7.5% povidon-iodide containing solution (Braunol®) and 
an alcohol-based disinfectant (Kodan®). A skin incision of about five centimeters 
length was made in the sulcus jugularis. The carotic artery and the external jugular 
vein were exposed, surrounding connective tissue was removed and two fixation 
sutures were placed proximally and distally around the artery and vein respectively. 
Following arteriotomy/venotomy a CBAS® Heparin Coated catheter was inserted 15 
cm into the artery and vein respectively. A proximal and distal ligature was applied to 
inhibit blood reflux and hold catheters in place. Subsequently, the operation wound 
was sutured in two layers and Leukase® N Kegel (Dermapharm AG) were placed 
between the tissue layers to provide local analgesia. For external fixation the catheters 
were tunneled separately through the skin up to the back of the neck using a tunneling 
instrument and were fixed with single-sutures to the skin, covered with gauze and 
secured with tape. Post-surgical analgesia was provided by intravenous injection of 
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Metamizol (50 mg/kg BW) for two days and cefquinom 2.5% was administered intra-
muscularly once daily for three days (2 mL per 25 kg BW) to prevent infections of the 
surgical site. Both catheters were flushed once daily with 50 IU heparin/mL 0.9% 
isotonic sodium chloride solution. Glucose clamps were performed following a 
recovery period of one week. Catheter placement was performed by Dr. Simone 
Renner (Chair for Molecular Animal Breeding and Biotechnology, LMU Munich). 
3.4.3.2. Hyperinsulinemic-euglycemic clamp (HIC) 
HICs were performed to directly assess insulin sensitivity in vivo and to uncover 
insulin resistant states (DEFRONZO et al., 1979). During HIC, insulin is infused at a 
constant rate while variable rates of glucose are infused in parallel in order to maintain 
euglycemia. Once steady state conditions are achieved, the glucose infusion rate is a 
direct measure of glucose uptake by insulin-sensitive peripheral tissues and therefore 
a direct measure of whole body insulin sensitivity. Prior to the HIC, sows were fasted 
overnight. At the day of the HIC sows were placed in individual and space-restricted 
pens to avoid free movement. Plasma insulin concentration was raised by insulin 
infusion (Insuman® rapid) at a rate of 1 mU/kg BW/min into the jugular vein. Blood 
glucose was clamped at a level of 75 mg/dl. This euglycemic glucose level was 
maintained by variable glucose infusion rates using a 40% glucose solution. For 
determination of the glucose infusion rate blood glucose concentration was measured 
from arterial blood every five min. using a FreeStyle Precision® neo Glucometer 
(Abbott) until the end of test. Total clamp duration was 180 min. and steady-state was 
considered to be reached two hours following the start of the insulin infusion. During 
steady-state blood samples were collected in nine mL plasma EDTA collection tubes 
every ten min., i.e.at 130, 140, 150, 160, 170 and 180 min. relative to the start of the 
insulin infusion for further analyses. The glucose infusion rate (GIR) a measurement 
of whole body insulin sensitivity was expressed as mg of infused glucose per kg BW 
per minute. Blood samples were processed as described in 3.3.3. Plasma glucose and 
insulin levels were measured as described in 3.3.3.1and 3.3.3.2.  
3.4.3.3. Hyperglycemic clamp (HGC)  
HGCs were performed to evaluate β-cell function (DEFRONZO et al., 1979). During 
the HGC plasma glucose concentration was acutely raised to a certain hyperglycemic 
level by administration of a glucose bolus followed by a variable glucose infusion rate. 
Sows were placed in individual and space restricted pens following an 18-hour 
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overnight fasting period. Plasma glucose concentration was raised to 300 mg/dl by a 
glucose bolus followed by variable glucose infusion. To adjust glucose infusion rate 
blood glucose concentration was measured every five min. until the end of the assay 
at 90 min., using the HemoCue® Glucose 201+ Glucometer (Radiometer GmbH). 
Blood samples were collected in nine mL plasma EDTA collection tubes every ten 
min. throughout the entire test period. Fifty min. after the start of the glucose infusion 
an arginine bolus (5 g per animal) was injected into the jugular vein to determine 
maximal insulin secretion capacity. Following collection blood samples were 
processed as described in 3.3.3. Plasma glucose and insulin levels were measured as 
described in 3.3.3.1and 3.3.3.2. 
 Mixed-meal oral glucose tolerance test (MMGTT) 
MMGTTs during pregnancy were performed in three wt-np, nine wt-p and three 
INSC93S-p sows at gestational day 92 ± 3.61. The procedure was performed as 
previously described in 3.3.2.2. and samples were processed as described in 3.3.3. 
Plasma glucose and insulin levels were measured as described in 3.3.3.1and 3.3.3.2. 
 Phenotypic characterization of neonatal piglets  
The effects of chronic exposure to mild hyperglycemia during gestation were 
investigated in neonatal wt piglets born to wt and INSC93S tg sows. In the following 
chapters wt piglets born to INSC93S tg sows are referred to as wt/tg and wt piglets born 
to wt sows are referred to as wt/wt respectively.  
 Glucose challenge tests in newborn piglets  
3.5.1.1. Oral glucose tolerance test (OGTT) 
OGTT were performed in neonatal piglets (wt/wt: n=18, and wt/tg: n=13) born to three 
tg and two littermate wt sows. The principle of an OGTT is the same as of an MMGTT 
with the exception that during an OGTT solely a glucose bolus is administrated 
through a nasogastric tube. Therefore, this procedure is suitable for suckling piglets 
which cannot yet digest a meal. Piglets were separated from the sows immediately 
after birth to avoid first colostrum uptake. Subsequently, animals were weighed. 
Following a recovery period of 15-30 min. after birth a bolus of 50 % glucose solution 
(2 g/kg body weight) was administrated via a nasogastric tube. Blood glucose 
concentrations were measured at time points 0, 15, 30, 45, 60, 90 and 120 min. relative 
to the glucose load from blood drops taken from a superficial ear vein with a FreeStyle 
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Precision® neo Glucometer. In addition, one mL blood samples were collected at time 
points 0, 30, 60 and 120 min. in nine mL plasma EDTA collection tubes from the 
jugular vein and processed as described in 3.3.3. Plasma glucose and insulin levels 
were measured as described in 3.3.3.1and 3.3.3.2. 
3.5.1.2. Assessment of plasma metabolites by spectrophotometry.  
EDTA-plasma samples collected during the OGTT (time point 0 and 120 min. relative 
to the glucose load) were assessed for different clinical chemical parameters (Table 7) 
of six wt/tg and six wt/wt piglets that were randomly selected from all five sows (two 
wt/tg piglets from each of the three INSC93S transgenic sows and three wt piglets from 
each of the two wt sows). Analyses were performed by spectrophotometry (Beckman 
& Coulter AU480 Analyzer) as previously described in 3.3.3.1  
Table 7:  Clinical chemical parameters 
 Carbohydrate metabolism Glucose 
Lactate 
LDH 
 Lipid metabolism Cholesterol 
HDL 
LDL 
Lipase 
NEFA 
Triglycerides 
Non esterified fatty acids (NEFA) 
 Necropsy 
At day one of age 12 wt/wt and 13 wt/tg piglets underwent necropsy. Anesthesia was 
induced by intramuscular injection of ketamine (20 mg/kg BW) and azaperone 
(2 mg/kg BW) followed by euthanasia via intra-cardial injection of Embutramid, 
Mebezonium, Tetracain (T61, 4 - 6 mL T 61 / 50 kg BW). Subsequently, BW, crown-
rump length (CRL) and organ weights (heart, kidneys, liver, lung, pancreas, spleen) 
and the weight of the carcass defined as the whole body excluding all organs but 
including head and brain were recorded. Relative CRL and relative organ weights were 
determined by dividing the absolute organ weights by the BW of respective piglet.  
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 Statistical analysis  
All data are presented as means ± standard error of the mean (SEM). The results of 
oral, mixed-meal and intravenous glucose tolerance tests as well as glucose clamps 
(GIR) were statistically evaluated by analysis of variance (PROC MIXED; SAS 8.2) 
taking the fixed effects of Group (INSC93S vs. wt control), Time (relative to glucose 
administration, steady-state during HIC) and interaction of Group*Time into account. 
Statistical differences regarding clinical-chemical parameters were evaluated by 
analysis of variance (General Linear Models; SAS 8.2) taking the fixed effects of 
Group (wt/tg vs. wt/wt), Time (0 min. and 120 min.) and the interaction Group*Time 
into account. Absolute and relative BW, CRL and organ weights were statistically 
evaluated by analysis of variance (PROC GLM; SAS 8.2) taking the fixed effect of 
Group (wt/tg vs. wt/wt) into account. Differences between two groups regarding 
quantitative-stereological analyses, expression levels and areas under the 
glucose/insulin curve were evaluated by Mann-Whitney-U test in combination with an 
exact test procedure (SPSS 21.0). Area under the curve (AUC) for insulin and glucose 
were calculated using Graph Pad Prism® software (version 5.02). P values less than 
0.05 were considered to be significant. 
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IV. RESULTS 
1. Generation of INSC93S transgenic pigs by SCNT 
Transgenic pigs were established by additive gene transfer and SCNT technology. As 
a result of the amino acid exchange in the coding sequence of the insulin gene, the 
disulfide bond within the A-chain is disrupted and consequently a misfolded proinsulin 
protein is generated Figure 3). The mutant insulin accumulates in the endoplasmic 
reticulum by formation of high-molecular-weight complexes possibly interfering with 
the secretion of the endogenous insulin (Liu et al. 2010).  
 
A total of 503 INSC93S transgenic reconstructed embryos were transferred into the 
oviducts of five cycle-synchronized recipient gilts from which two pregnancies went 
to term (Table 8). Five out of ten piglets were born alive. The overall efficiency of 
nuclear transfer experiments from the two established pregnancies was 2.42 % 
(calculated by the total number of alive piglets of pregnancy 1 and 3 per respective 
number of transferred embryos).  
 
Figure 3: Proinsulin amino acid sequence 
Proinsulin amino acid sequence composed of the A-chain, B-chain and the connecting 
peptide (C-peptide). The A- and B-chain of the insulin are connected by two interchain 
and one intrachain disulphide bonds. The arrow depicts the amino acid exchange 
cysteine to serine at position 93 (C93S) within the mutant insulin.  
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Table 8: Overview of NT experiments 
Embryo 
Transfer 
Somatic 
cells 
Transferred 
embryos 
Pregnancy 
established 
Delivered 
piglets 
Alive 
piglets 
      
1 PFF 14 95 + 3 
(9748- 
9750) 
2 
(9748, 
9750) 
2 PFF 14 95 - - - 
3 PFF 26 112 + 7 
(9772- 
9778 
3 
(9774, 
9776, 
9777) 
4 PFF 26 101 - - - 
5 PFF 26 100 - - - 
Total -  503 2/5 10 5 
  
Porcine fetal fibroblasts (PFF) 
 Identification of INSC93S transgenic pigs by PCR and Southern blot 
PCR experiments using transgene specific primers were used to identify INSC93S 
transgenic animals. Figure 4 shows a representative example of an INSC93S 
genotyping PCR, in which four out of nine animals were identified as INSC93S 
transgenic pigs. In addition, Southern blot experiments were performed to prove 
correct identification of transgenic animals by PCR, as well as to identify the number 
of integration sites of the INSC93S transgene. 
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Figure 5 depicts an example of Southern blot experiments of all founder boars from 
embryo transfer n°3 and F1 offspring of founder 9776. Integration of the INSC93S 
transgene could be detected in founders (9773 – 9778) (Figure 5 A). According to the 
expression level and results from the glucose tolerance test (see 1.2 and 2.1) founders 
9748 and 9776 were selected for further characterization and mated to wildtype sows. 
Southern blot analyses of F1 offspring from founder 9748 (data not shown) and 9776 
(Figure 5 B) showed the same transgene integration pattern as the respective founder 
boar, confirming germline transmission of the INSC93S transgene and a single 
integration site in the genome in these two lines.  
Figure 4: Identification of INSC93S transgenic pigs by PCR 
(A) INSC93S PCR for detection of the INSC93S transgene; (B) ACTB PCR using the 
same genomic DNA samples for the control of DNA integrity; (tg): INSC93S transgenic 
pigs; (wt): non-transgenic littermate control pigs; M: 1kb DNA ladder marker; +: 
primer positive control (genomic DNA of a previously confirmed INSC93S tg pig); -: 
primer negative control (genomic DNA of a previously confirmed wt pig); W: internal 
negative control (distilled water).  
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Figure 5: Southern blot analysis of INSC93S founders and F1 offspring of founder 
9776 
X-ray exposed membranes, labeled with a transgene-specific radioactive probe for the 
detection of the INSC93S transgene in (A) seven INSC93S transgenic founder boars and 
(B) F1 offspring of founder 9776. The identical transgene integration pattern in F1 
offspring from founder 9776 argues for one single integration site of the INSC93S 
transgene.  
 
 Founders 9776 and 9748 exhibited the highest INSC93S expression level 
Next, gene expression analyses of pancreatic tissue from the five living founder boars 
(9776, 9748, 9777, 9750 and 9774) as well as from F1-offspring of founder boar 9748 
and 9776 were performed. Good quality RNA according to the presence of distinct 
28S and 18S ribosomal RNA bands without considerable RNA degradation was 
obtained from all animals and was reverse transcribed. RT-PCR using insulin-specific 
primers was run to determine the presence of insulin transcripts. Insulin cDNA 
transcripts were detected in all five founders as well as in F1 offspring from founder 
9748 and 9776 (Figure 6 A). RT-PCR with ACTB primers was run on the same cDNA 
samples as internal positive control. A signal of equal intensity was detected in all 
animals indicating that RNA was successfully reverse transcribed into cDNA (Figure 
6 B). Minus RT control PCR revealed no signal (Figure 6 C) indicating complete 
DNase digest and excluding genomic DNA contamination of cDNA samples. 
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Next, INSC93S/INS ratios were determined from cDNA amplicons by next generation 
sequencing. Founder 9776 exhibited the highest INSC93S/INS ratio (0.599), followed 
by founders 9748 (0.315), 9777 (0.169), 9750 (0.051) and 9774 (0.002). Transgenic 
F1 piglets exhibited similar INSC93S/INS ratios as their respective founders: F1 
offspring of founder 9776 (0.552 ± 0.035, n=3) and F1 offspring of founder 9748 
(0.304 ± 0.006, n=3) (Figure 7).  
Figure 6: RT-PCR products 
(A, B, C) PCR products from cDNA samples of five founder boars and F1-offspring 
from founder 9748 and 9776. (A) INSC93S PCR, (B) ACTB PCR and (C) DNaseI 
digested RNA products proving no genomic DNA contamination; M: pUC Mix 
molecular weight marker; gDNA: positive control (genomic DNA); W: distillated 
water as non-template control. 
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2. Phenotypic characterization of INSC93S transgenic pigs 
 INSC93S transgenic founders exhibited unaltered (fasting) blood glucose 
levels but impaired intravenous glucose tolerance 
Following expression analysis, effects of INSC93S expression on non-fasting and fasting 
blood glucose levels were assessed in the five INSC93S transgenic founder boars. Data 
were collected from fed animals between 15 to 46 days of age (prior to weaning) and 
after an overnight fasting period between 52 and 207 days of age (after weaning). All 
founders exhibited (fasting) glucose concentrations within the normal range for pigs 
(Figure 8). Therefore, INSC93S transgenic founders have unaltered fasting blood 
glucose levels.  
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Figure 7: Expression levels of the INSC93S transgene   
Quantification of INSC93S/INS transcript ratios by next-generation sequencing of the 
five living founder boars as well as of F1-offspring from founder 9748 and 9776.
Founders 9776 and 9748 exhibited the highest expression levels of the INSC93S
transgene. F1 offspring revealed similar INSC93S/INS ratios as their respective founders.
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In addition, effects of INSC93S expression on glucose tolerance were investigated in an 
IVGTT in the five living INSC93S transgenic founders and two age-matched wt animals. 
At the time of the IVGTT the animals were 237 ± 3.67 days old. After intravenous 
glucose bolus (0.5 g/kg body weight), transgenic founders 9776 and 9748 revealed 
decelerated decline of blood glucose and distinctly reduced insulin secretion compared 
to transgenic founders 9750, 9774, 9777 and wt controls (Figure 9A and B). These 
findings are in line with gene expression data. Founders 9776 and 9748, which 
exhibited the highest INSC93S expression levels (shown previously in Figure 7D), 
revealed an aggravated phenotype in terms of glucose control as compared to founders 
9750, 9774 and 9777.  
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Figure 8: (Fasting) blood glucose levels in INSC93S transgenic founder boars
Non-fasted values represent measurements before weaning. After weaning, 
glucose levels were determined after an 18-hour fasting period. Highlighted in 
grey is the reference range of blood glucose for pigs.  
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According to the gene expression and IVGTTs results, founders 9776 and 9748 
revealed the highest expression levels of the mutant insulin C93S, as well as an 
impaired glucose clearance and insulin secretion phenotype therefore, they were mated 
with wt sow and effects on F1 offspring were evaluated. Data from F1 offspring from 
founder 9766 is presented. The data from 9748 is mentioned in the text.  
 Body weight is unaltered in INSC93S transgenic pigs  
BW gain was assessed in F1 offspring from founder boar 9748 and 9776. Data were 
collected in regular intervals from 57 to 175 days of age in F1 offspring from founder 
9776 and eight to 168 days of-age in offspring from founder 9748. There were no 
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Figure 9: Intravenous glucose tolerance in INSC93S tg founder boars 
IVGTTs of 8-months-old INSC93S transgenic founders depict impaired intravenous 
glucose tolerance of founders 9776 and 9748. (A) Plasma glucose concentration; (B)
plasma insulin concentration. INSC93S transgenic (tg) and age-matched wt controls (wt). 
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significant differences observed in body weight gain between INSC93S transgenic and 
wt animals of both lines (Figure 10).   
    
 
 
To evaluate the effect of INSC93S expression on glucose metabolism, IVGTTs and 
MMGTTs were performed at four and seven months of age. INSC93S transgenic and wt 
animals from the F1 and F4 generation were included in the tests.  
 INSC93S transgenic pigs showed reduced oral and intravenous glucose 
tolerance at four and seven months of age  
IVGTTs were performed in 4- and 7-month-old transgenic pigs (n=11) and eight 
littermate controls. Fasting plasma glucose (FPG) levels at four and seven months were 
significantly elevated in INSC93S transgenic pigs compared to wt controls (FPG4 months 
= 136.4 ± 6.108 vs. 88.8 ± 4.010, p= 0.006) (Figure 11 A) and (FPG7 months = 133.4 ± 
9.173 vs. 73.9 ± 4.430, p= 0.0014) (Figure 12 A). Fasting plasma insulin was reduced, 
but not significantly, in INSC93S transgenic animals compared to controls at both ages 
(Insulin 4 months = 5.939 ± 1.139 vs. 8.348 ± 0.929, p=0.5842) (Figure 11 C) and (Insulin 
7 months = 6.629 ± 0.712 vs. 11.471 ± 1.050, p=0.348) (Figure 12 C). After an 
intravenous glucose challenge (0.5 g/kg body weight), INSC93S transgenic animals 
exhibited significantly elevated plasma glucose levels and reduced insulin secretion 
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Figure 10: Unaltered body weight gain in INSC93S transgenic pigs. 
Body weight measurement in F1-offspring of founder 9776. There were no significant 
differences between the two groups at any time point. Data are means ± SEM.  
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compared to non-transgenic littermates both at four and seven months of age (Figure 
11 A, C and Figure 12 A, C). Glucose tolerance was significantly reduced in INSC93S 
transgenic pigs at both ages tested. This was demonstrated by a reduced glucose 
clearance resulting in an increased area under the glucose curve (AUC glucose) at four 
months (AUC glucose 4 months = 21156 ± 879 vs. 12812 ± 841, p<0.001) (Figure 11 A, 
B), as well as at seven months of age (AUC glucose 7 months = 21766 ± 1126 vs. 10841 
± 286, p<0.001) (Figure 12  A, B). In parallel, the AUC of insulin was significantly 
reduced in INSC93S transgenic pigs as compared to wt littermates at four and seven 
months of age, respectively (AUC insulin 4 months = 1132 ± 150 vs. 2479 ± 248, 
p<0.001) (Figure 11 C, D) and (AUC insulin 7 months = 1301 ± 138 vs. 2797 ± 251, 
p=0.001) (Figure 12 C, D). Although there were no significant gender-related 
differences in glucose tolerance at four months of age (data not shown), INSC93S 
transgenic females revealed an aggravated impairment of glucose tolerance compared 
to INSC93S tg males at seven months of age (AUC glucose 7 months = 23694 ± 1576 vs. 
19453 ± 892, p<0.05) (Figure 13 A, B). In line with glucose levels, impaired insulin 
secretion was aggravated in INSC93S tg females as compared to INSC93S tg males (AUC 
insulin 7 months = 1011 ± 112 vs. 1650 ± 174, p<0.05) (Figure 13 C, D). These results 
demonstrate that INSC93S transgenic pigs showed significantly reduced FPG levels as 
well as a distinct impairment of intravenous glucose tolerance and reduced insulin 
secretion that was stable in its manifestation between four and seven months of age. 
Moreover, INSC93S transgenic females developed a more pronounced impairment of 
glucose tolerance compared to INSC93S transgenic males only at seven months of age.  
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Figure 11: Intravenous glucose tolerance in 4-month-old INSC93S transgenic pigs 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; INSC93S transgenic pigs 
(tg) and non-transgenic controls (wt) of the F1 and F4 generation; data are means ± 
SEM; (*) p<0.05; (**) p<0.01; (***) p<0.001.  
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Figure 12: Intravenous glucose tolerance in 7-month-old INSC93S transgenic pigs 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; INSC93S transgenic 
animals (tg) and non-transgenic littermate control animals (wt) of the F1 and F4 
generation; data are means ± SEM; (*) p<0.05; (**) p<0.01; (***) p<0.001.  
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Furthermore, the same animal group was subjected to MMGTTs. Oral digestion of 
dietary constituents present in a standard mixed meal combined with a glucose bolus 
represents a more physiological test compared with the intravenous glucose challenge. 
Following oral glucose uptake, glucose-induced insulin secretion is potentiated by 
incretin hormones produced in enteroendocrine cells and also other factors like gastric 
emptying play a role for glucose clearance and are not considered following an 
intravenous glucose bolus. MMGTTs were performed in 4-month-old transgenic pigs 
(n=11) and seven wt littermate controls as well as in 7-month-old transgenic pigs (n=9) 
and six littermate controls. FPG levels tended to be reduced at 4 months of age and 
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Figure 13: Intravenous glucose tolerance in 7-month-old INSC93S transgenic pigs, 
gender effects 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; INSC93S transgenic 
animals (tg) and non-transgenic littermate control animals (wt); (m) male; (f) female; 
data are means ± SEM; (*) p<0.05. 
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were significantly reduced at seven months of age in INSC93S transgenic pigs as 
compared to controls (FPG4months= 144.0 ± 8.085 vs. 88.1 ± 2.870, p= 0.058) and 
(FPG7months= 140.7 ± 14.066 vs. 81.9 ± 1.286, p=0.036) (Figure 14 A and Figure 15 
A). Like in IVGTTs, fasting plasma insulin levels were unaltered in both age groups 
(Insulin 4 months = 9.234 ± 1.159 vs. 9.471 ± 1.396, p= 0.9676) and (Insulin 7 months = 
7.574 ± 0.818 vs. 9.811 ± 1.642, p= 0.7986) (Figure 14 C and Figure 15 C). After an 
oral glucose challenge (2 g/kg body weight) mixed with commercial pig food adjusted 
for body weight, blood glucose concentrations started to increase at time point 15 
minutes relative to the oral glucose plus food load in both groups. In both age groups, 
glucose tolerance was reduced in INSC93S tg animals as compared to wt controls (AUC 
glucose 4 months = 29051 ± 2834 vs. 13209 ± 497, p<0.001) and (AUC glucose 7 months = 
26489 ± 2764 vs. 12891 ± 582, p<0.001) (Figure 14 A, B and Figure 15 A, B). In line 
with increased glucose levels, insulin secretion was reduced in INSC93S transgenic 
animals. Although at four months of age, total AUC insulin was not different from wt 
animals (AUC insulin 4 months =3801 ± 403 vs. 4121 ± 341, p=0.651), INSC93S transgenic 
pigs showed a significant delay in peak insulin secretion. While wt animals reached 
maximum plasma insulin levels at 30 min, INSC93S transgenic pigs reached their 
maximum insulin levels only at 90 min, and the insulin peak level of tg animals never 
reached that of non-transgenic controls (AUC 4 months 0-30min = 1202.7 ± 135.882 vs. 
643.0 ± 71.417, p=0.007) (Figure 14 C, D). However, at seven months of age, insulin 
secretion was significantly reduced in INSC93S transgenic pigs (AUC 7 months = 2901 ± 
324 vs. 5627 ± 863, p<0.05) (Figure 15 C, D). Compared with insulin secretion four 
months of age, INSC93S transgenic pigs secreted 24 % less insulin at seven months of 
age (AUC 4 months = 3801.4 ± 403.241 vs. AUC 7 months = 2901 ±324, p=0.197) ( Figure 
15 E). 
In addition, two patterns of insulin curves in wt animals were observed during the 
MMGTT: a monophasic curve at four months and a biphasic curve at seven months of 
age. In the monophasic curve, insulin concentrations peaked at 30 minutes (50.8 ± 
4.269 µU/mL) after the glucose intake and started to constantly decrease thereafter 
(Figure 14 B). In the biphasic curve two insulin peaks were observed. A first insulin 
peak (56.0 ± 13.689 µU/mL) at 30 minutes followed by a decrease in insulin 
concentration up to 60 minutes and a second insulin peak (70.2 ± 17.128 µU/mL) that 
occurred at 90 minutes followed by a constant decrease in insulin concentration until 
the end of the MMGTT, i.e. at 120 minutes (Figure 15 B). These fluctuations were 
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observed in parallel to the respective glucose curves. INSC93S transgenic animals only 
revealed monophasic curves. In summary, INSC93S transgenic pigs showed impaired 
oral glucose tolerance at four and seven months of age. Different from IVGTT, insulin 
secretion was delayed but not reduced at four months and reduced at seven months of 
age.  
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Figure 14: Oral glucose tolerance in 4-month-old INSC93S transgenic pigs 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; INSC93S transgenic pigs 
(tg) and non-transgenic littermate control animals (wt) from F1 and F4 generation; 
data are means ± SEM; (*) p<0.05; (**) p<0.01; (***) p<0.001. 
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Figure 15: Oral glucose tolerance in 7-month-old INSC93S transgenic pigs. 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; (E) AUC insulin at four 
and seven months; INSC93S transgenic pigs (tg) and non-transgenic littermate control 
animals (wt); data are means ± SEM; (*) p<0.05; (**) p<0.01; (***) p<0.001. 
 
F1-offspring from founder boar 9748 revealed a similar phenotype, i.e. reduced 
glucose tolerance and insulin secretion in an IVGTT and OGTT at four and seven 
months of age. However, the effect of INSC93S expression on FBG levels was less 
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pronounced. Therefore, all further investigations were performed in offspring from 
founder 9776. 
 Low-grade reduction of the total β-cell volume in INSC93S pigs   
Next, total β-cell volume was investigated. In total, four INSC93S transgenic and three 
age-matched wildtypes were analyzed. At the time of necropsy animals were 
389 ± 19.5 days of age. No significant difference in pancreas weight between INSC93S 
transgenic animals and wt controls could be detected at the time of necropsy (217.9 ± 
15.0 vs. 191.8 ± 26.6, p=0.289), respectively. Quantitative stereological analysis of the 
pancreas revealed a reduced, although not significant, total β-cell volume in INSC93S 
transgenic pigs compared to wt littermates. Volume density of β-cells in the pancreas 
and total β-cell volume was reduced by 35 % (Vv(β-cell/Pan) = 0.875 ± 0.07, n=4 vs 1.34 
± 0.29, n=3, p=0.114) and 22 %, (V(β-cell,Pan) = 1779.34 ± 198.16, n=4 vs. 2295.70 ± 
355.89, n=3, p= 0.114), respectively Figure 16 A and B). 
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Figure 16: Quantitative stereological analysis of the pancreas 
(A) Volume density of β-cells in the pancreas (Vv(β-cell/Pan)) and (B) total β-cell 
volume (V(β-cell, Pan)); total β-cell volume is decreased by 22 % in tg pigs compared 
to non-transgenic littermates (p=0.114). Data are means ± SEM; ns: p>0.05.  
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3. Phenotype of INSC93S tg sows during pregnancy 
Next, glucose and insulin metabolism in the context of pregnancy were investigated. 
Physiological metabolic changes during pregnancy, were characterized in wt-pregnant 
(wt-p) sows compared with wt non-pregnant (wt-np) controls, hence, serving as a 
control group for the effects of pregnancy in sows. Moreover, metabolic changes in 
prediabetic INSC93S transgenic pregnant sows (INSC93S-p) were investigated. 
 Fasting glucose levels in INSC93S transgenic sows during pregnancy 
Eighteen hours fasting glucose levels were monitored twice weekly in INSC93S-p (n=3), 
wt-p (n=4), INSC93S-np (n=3) and wt-np (n=4) during gestational week three to sixteen. 
Pregnant and non-pregnant INSC93S transgenic sows exhibited similar significantly 
elevated fasting glucose levels (INSC93S-p: 88.952 ± 2.122 and INSC93S-np: 90.306 ± 
2.888) compared to wt-p (53.330 ± 0.858 and wt-np 50.330 ± 1.119) sows (p< 0.0001) 
(Figure 17 A, B). No further increase in fasting glucose levels was observed during 
pregnancy in INSC93S-p sows compared to INSC93S-np sows (Figure 17 A, B). This was 
also the case in wt-p and wt-np sows. These results indicate that pregnancy did not 
affect fasting glucose levels of wt and INSC93S transgenic sows. 
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Figure 17: Fasting glucose levels in INSC93S transgenic sows during pregnancy 
(A) Fasting glucose concentrations from gestational week three to 16. (B) Mean 
glucose levels from gestational week three to 16 of pregnant (INSC93S-p) and non-
pregnant (INSC93S-np) INSC93S transgenic sows as well as pregnant (wt-p) and non-
pregnant (wt-np) wildtype sows. Data are means ± SEM. a, b: different letters depict 
significant differences.  
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 Insulin sensitivity is reduced to the same extent in pregnant INSC93S 
transgenic and wt sows 
HIC were performed to investigate changes in insulin sensitivity during pregnancy 
(gestational week 80 ± 2.30). Initially, insulin sensitivity of wt-p (n=4) and wt-np 
(n=3) was investigated. In a second step, insulin sensitivity in the pregnant state of wt-
p (n=4) and INSC93S-p (n=3) was evaluated. Steady state conditions were successfully 
achieved at 130 min in the two groups. This was shown by constant glucose infusion 
rates during 130 and 180 minutes. Additionally, plasma insulin (wt-p 0.374 ± 0.057 
ng/mL vs. wt-np 0.321 ± 0.047 ng/mL, p=0.488 and  tg-p 0.383 ± 0.060ng/mL vs. wt-
p 0.450 ± 0.065 ng/mL, p=0.456) and glucose (wt-p 67.2 ± 1.880 mg/dl vs. wt-np 67.1 
± 1.965 mg/dl, p= 0.968 and tg-p 70.3 ± 4.066 mg/dl vs. wt-p 70.9 ± 1.656 mg/dl, p= 
0.893) levels were maintained during that period in all four groups (Figure 18 A and 
Figure 19 A). GIR was reduced by 35 % in wt-p sows compared with wt-np (9.020 ± 
0.267 vs. 14.064 ± 0.930, p = 0.028) (Figure 18 B and C), whereas GIR in INSC93S-p 
sows was reduced to the same extend as in wt-p sows (6.335 ± 0.456 vs 6.834 ± 0.317, 
p=0.633) (Figure 19 B and C). Importantly, the coefficient of variance (CV) of the 
GIR during the steady state was ≤5 % in both groups (wt-p 4.53 % vs. wt-np 5.13 % 
tg-p 4.62 % vs. wt-p 3.0 %). Taken together, these results demonstrate that pregnancy 
reduced insulin sensitivity in pigs, however, insulin sensitivity in pregnant INSC93S 
transgenic sows was not further impaired compared to wt-p sows. 
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Figure 18: Hyperinsulinemic-euglycemic clamps in wt sows during pregnancy 
(A) Plasma glucose and insulin concentrations during steady-state of the HIC. (B) 
Glucose infusion rate (GIR) during steady-state. (C) Average GIR during steady 
state. Pregnant wildtype sows (wt-p); non-pregnant wildtype sows (wt-np); Data are 
expressed as means ± SEM. (*) p<0.05, (**) p<0.01, (***) p<0.001.  
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Figure 19: Hyperinsulinemic-euglycemic clamps in tg sows during pregnancy 
(A): Plasma glucose and insulin concentrations during steady-state of the HIC. (B) 
Glucose infusion rate (GIR) during steady-state. (C) Average GIR during steady 
state. Pregnant INSC93S transgenic sows (INSC93S-p); pregnant non-transgenic 
controls (wt-p); Data are expressed as means ± SEM. (*) p<0.05, (**) p<0.01, (***) 
p<0.001.   
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 ß-cell function is significantly impaired in INSC93S-p sows 
HGC tests were performed to assess β-cell function of INSC93S-p and wt-p sows 
(gestational week 86 ± 2.82). Animals were clamped at a hyperglycemic level of 300 
mg/dl (INSC93S-p 326.7 mg/dl ± 4.97 vs. wt-p 326.6 mg/dl ± 10.03, p= 0.993) by a 
variable infusion of a 40% glucose solution during the time course of the clamp (Figure 
20 A). First phase insulin secretion (0-10 min) did not significantly differ between 
INSC93S-p and wt-p sows (0.114 ng/mL ± 0.006 vs 0.264 ± 0.073, p= 0.189) (Figure 
20 B). However, second phase insulin response (10-90 min) was significantly impaired 
in INSC93S-p compared with wt-p sows as indicated by significantly lower plasma 
insulin concentrations in all time points (Figure 20 B). Overall total insulin response 
was 71 % reduced in INSC93S-p sows compared to wt-p sows (AUC= 19.9 ± 5.49 vs 
79.7 ± 8.81, p= 0.0045) (Figure 20 C). Correspondingly, the reduced insulin secretion, 
GIR was lower in INSC93S-p compared with wt-p sows, and significantly different at 
time points 20, 25, 60 and 70 min (Figure 20 D). However, total GIR did not reach 
significance between INSC93S-p and wt-p sows (9.041 ± 0.324 vs. 12.694 ± 1.368, 
p=0.077) (Figure 20 D and E). Both INSC93S-p and wt-p responded with increased 
insulin secretion to the arginine bolus at 50 min (Figure 20 B). Despite the reduced 
insulin secretion in INSC93S-p, the increment in insulin response (50 to 60 min) 
following the arginine bolus was not different compared to wt-p (0.141 ± 0.03 vs 0.214 
± 0.026, p=0.229). Together these results indicate that INSC93S-p sows have reduced 
insulin secretion, reflecting impaired β-cell function.   
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Figure 20: Hyperglycemic clamps during pregnancy 
(A) Plasma glucose concentration; (B) Plasma insulin levels; (C) Area under the 
insulin curve (AUC insulin); (D) Glucose infusion rate (GIR); (E) Mean glucose 
infusion rate; pregnant INSC93S transgenic sows (INSC93S-p); pregnant non-transgenic 
littermate controls (wt-p); - non-pregnant controls (wt-np); Date are expressed as 
means ± SEM; (*) p<0.05; (**) p<0.01; (***) p<0.001. 
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 Low-grade impairment of glucose tolerance in wt-p and pronounced 
impairment in INSC93S-p sows 
MMGTs were performed in nine wt-p, three INSC93S-p and three age-matched wt-np 
sows. This allowed characterization of glucose metabolism and insulin response in 
wild-type pigs during pregnancy, as well as to investigate how INSC93S transgenic sows 
respond to extra metabolic demands during the pregnant state as compared to wt-p 
sows. Wt-np and wt-p pigs showed unaltered fasting glucose levels (65.0 ± 0.996 vs. 
67.0 ± 4.272 mg/dl, p=0.863), whereas INSC93S-p sows exhibited significantly 
elevated, borderline hyperglycemic values (104.8 ± 1.530, p<0.01) (Figure 21 A). 
Although INSC93S-p sows exhibited elevated fasting glucose, fasting insulin levels did 
not differ from wt-p control sows (5.45 ± 3.17 vs. 7.33 ± 1.77, p= 0.911) (Figure 21 
B). Upon oral glucose challenge (2 g/kg body weight), glucose levels rose in all three 
groups and reached maximum levels at 30 min for both wt-np and wt-p sows, 
respectively (93.7 ± 2.554 and 114.1 ± 5.027 mg/dl, p=0.077). INSC93S-p sows showed 
rising glucose levels until 60 min (209.7 ± 1.888 mg/dl). From 30 min after oral 
glucose load, wt-p sows had significantly elevated glucose levels until the end of the 
MMGTT as compared to wt-np sows, but glucose levels were significantly lower than 
in INSC93S-p sows for all time points (Figure 21 A). This resulted in a significantly 
increased AUC glucose in wt-p as compared to wt-np (AUC= 3866 ± 642.8 vs. 1254.9 
± 183.1, p<0.01) (Figure 21 B) but significantly reduced AUC glucose compared with 
INSC93S-p sows (3866 ± 642.8 vs. 8754.7 ± 989.6, p<0.05) (Figure C). Insulin response 
was enhanced in wt-p and impaired in INSC93S-p sows compared to wt-np. Wt-p sows 
which showed significantly higher glucose levels than wt-np sows secreted 
significantly more insulin from time point 30 min compared to wt-np sows (Figure 21 
D). Despite not significant, AUC insulin of wt-p tended to be higher than AUC insulin 
of wt-np (7984 ± 881.1 vs. 4726.7 ± 682.0, p=0.0636) (Figure 21 E). In parallel, tg-p 
sows which showed impaired glucose tolerance revealed reduced and delayed insulin 
secretion as compared to wt-p sows (Figure 21 B). This led to a significant reduction 
in AUC insulin between tg-p and wt-p sows (4607.7 ± 119.2 vs. 7984 ± 881.1, p<00.1) 
(Figure 21 F).  
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Figure 21: MMGTT during pregnancy. 
(A) Plasma glucose levels; (B, C) AUC glucose: area under the glucose curve; (D) 
Plasma insulin levels; (E, F) AUC insulin: area under the insulin curve; pregnant 
INSC93S transgenic sows (INSC93S-p), pregnant non-transgenic control animals (wt-p) 
and non-pregnant, non-transgenic control animals (wt-np); Data are means ± SEM; a, 
b, c: different letters depict significant differences; (*) p<0.05; (**) p<0.01.  
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4. Effects of mild maternal hyperglycemia on offspring  
 Wt piglets born to mild diabetic INSC93S transgenic sows revealed 
elevated FPG and a tendency of reduced glucose tolerance despite 
increased insulin secretion at birth 
Effects of chronic exposure to mild hyperglycemia in utero were investigated in 
newborn piglets. Differences in glucose metabolism and insulin response were 
investigated during OGTTs at birth in 18 wt piglets born to wt sows and 12 wt piglets 
born to INSC93S transgenic sows. At birth wt/tg piglets showed elevated glucose levels 
compared to wt/wt piglets (83.4 ± 9.353 vs. 54.133 ± 4.810, p= 0.0553) (Figure 22 A). 
Results from fasting insulin revealed that 58 % of wt/tg piglets showed insulin 
concentrations above the detection limit of the ELISA (≤ 1.611 µU/mL) as compared 
to 11 % of wt/wt, suggesting that wt/tg piglets have higher insulin levels as compared 
to wt/wt piglets (Figure 22 B). Following oral glucose administration (2 g/kg body 
weight), wt/tg exhibited significantly elevated glucose levels from 30 min until the end 
of the OGTT (Figure 23 A). When corrected to baseline values, AUC glucose was not 
significant although, it tended to be higher in wt/tg compared to AUC glucose of wt/wt 
piglets, (14278.3 ± 1520.7 vs. 11438.6 ± 783.7, p=0.0790) (Figure 23 B). Insulin 
response to glucose load was also different in wt/tg piglets which exhibited elevated 
insulin levels especially at the end (120 min.) of the OGTT (27.8 ± 6.834 vs. 14.2 ± 
1.573, p<0.001) (Figure 23 C). Total AUC insulin of wt/tg piglets (corrected to 
baseline levels) tended to be higher than total AUC insulin from wt/wt (2108.2 ± 
380.967 vs. 1417.3 ± 234.390, p= 0.0864) (Figure 23 D). Together these results 
suggest that chronic exposure to maternal mild hyperglycemia has effects on early 
glucose response and insulin secretion in wt/tg piglets. 
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Figure 22: Fasting glucose and insulin levels at birth in offspring of INSC93S tg 
and wt control sows 
(A) Plasma glucose levels and (B) Plasma insulin levels in 18 wt/wt piglets and 12 
wt/tg piglets); wt piglets born to wt sows (wt/w); wt piglets born to INSC93S transgenic 
sows (wt/tg); dotted line depicts the detection limit of the insulin assay (1.611 µU/mL); 
(**) p<0.01.  
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 Prenatal exposure to mild hyperglycemia altered lipid metabolism and 
glycolysis-related metabolites in wt offspring. 
Plasma samples were collected at 0 and 120 min during OGTTs to determine changes 
in metabolites involved in carbohydrate and lipid. Six wt/tg and six wt/wt piglets were 
investigated. At birth (0 min), wt/tg piglets exhibited significantly increased 
concentrations of total cholesterol (43.4 ± 3.624 vs. 31.7 ± 2.826, p= 0.034) (Figure 
24 A), LDL (36.2 ± 2.360 vs. 29.4 ± 1.557, p=0.041) (Figure 24 B ) and HDL (19.4 ± 
1.777 vs. 14.0 ± 1.557, p=0.025) (Figure 24 C) compared to wt/wt. Triglycerides, 
NEFA and lipase were not changed (Figure 24 D, E and F). When comparing 
metabolite changes during OGTT (0 to 120 min), most of the alterations occurred in 
metabolites directly involved in glucose metabolism. Glucose was significantly 
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Figure 23: Oral glucose tolerance tests in newborn piglets. 
(A) Plasma glucose levels; (B) AUC glucose: area under the glucose curve; (C) Plasma 
insulin levels; (D) AUC insulin: area under the insulin curve; wt piglets born to wt 
sows (wt/wt); wt piglets born to INSC93S tg sows (wt/tg); Data are means ± SEM; (*) 
p<0.05; (**) p<0.01. 
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increased at 120 in both groups and was significantly different in wt/tg compared to 
wt/wt (208.1 ± 20.162 vs. 168.1± 14.231, p=0.0465) (Figure 25 A). Lactate 
concentrations decreased in both groups after 120 min but with less extended in wt/tg 
(4.413 ± 0.780 vs. 2.390 ± 0.185, p= 0.149) (Figure 25 B). LDH was significant 
increased after 120 in wt/tg compared to wt/wt (626.0 ± 79.845 vs. 452.0 ± 39.615, p= 
0.028) (Figure 25 and Figure 24 C). These results indicate that wt/tg piglets showed 
differential lipid profile at birth and key elements of the glycolysis pathway were 
differently regulated upon 120 min OGTT in wt/tg compared to wt/wt.  
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Figure 24: Lipid metabolic parameters in offspring of INSC93S tg sows and wt 
controls 
(A, B, C, D, E and F) Differential lipid parameters evaluated in plasma samples 
collected at 0 min (right after birth) and 120 min (time after oral glucose bolus). Data 
are means ± SEM, a, b and c: different letters depict significant differences.  
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 Unaltered morphological parameters in wt piglets chronically exposed 
to mild maternal hyperglycemia  
At the end of the study, body and organ weights were investigated in all 14 wt/tg and 
11 wt/wt piglets at day one of age. No significant difference in absolute and relative 
body weights, CRL and organ weights could be detected between the two groups. 
Although not significant, relative liver and heart weights tended to be higher in wt/tg 
compared wt/wt animals (Table 9).  
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Figure 25: Carbohydrate metabolic parameters in offspring born to INSC93S tg 
sows and born to wt controls 
(A, B and C) Carbohydrate parameters of the glycolytic pathway evaluated in plasma 
samples collected at 0 min (right after birth) and 120 min (time after oral glucose 
bolus). Data are means ± SEM, a, b and c: different letters depict significant 
differences.  
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Table 9: Body and organ weights in 1-day-old piglets 
Parameter LSMeans Pvalue 
 wt/tg wt/wt  
    
Body weight (day 0) (g) 1358.775 1399.369 0.756 
Body weight (day 1) (g) 1473.806 1476.686 0.974 
CRL (cm) 28.223 28.559 0.785 
relCRL 2.550 2.583 0.676 
Pancreas (g) 2.109 1.998 0.549 
relPancreas 0.141 0.138 0.649 
Liver (g) 44.338 40.929 0.429 
relLiver  3.001 2.762 0.067 
Heart (g) 12.593 11.536 0.349 
relHeart  0.851 0.789 0.066 
Kidneys (g) 5.505 5.815 0.572 
relKidneys 0.371 0.395 0.265 
Lungs (g) 43.024 46.475 0.280 
relLungs 2.982 3.196 0.222 
Spleen (g) 2.130 2.093 0.888 
relSpeen 0.142 0.141 0.980 
Carcass (g) 1149.384 1142.208 0.936 
relCarcass  78.267 77.783 0.758 
Relative to the body weight (rel)
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V. DISCUSSION 
Maternal hyperglycemia is detrimental for the fetus as it increases the risk to develop 
metabolic diseases as obesity or diabetes in adulthood. Effects of maternal diabetes 
and underlying mechanisms are difficult to study in humans and have not been fully 
clarified by animal models. Transgenic pigs expressing the mutant insulin C93S were 
characterized before and during pregnancy. This novel animal model enables the 
investigation of deleterious effects of chronic intrauterine exposure to mild forms of 
hyperglycemia on the offspring at different developmental stages, e.g. embryo, fetus 
and offspring.  
1. Generation and phenotypic characterization of INSC93S 
transgenic pigs before pregnancy 
Five living INSC93S transgenic founders resulted from SCNT and embryo transfer 
experiments (KUROME et al., 2015). The nuclear transfer efficiency was 2.42 %, 
which is in line with the range of SCNT cloning efficiency (0.5 % to 5 %) in the pig 
(AIGNER et al., 2010). Different integration patterns of the INSC93S transgene among 
the five INSC93S founders were observed in Southern blot analyses (Figure 5 A). This 
result is expected as these animals resulted from pools of stably transfected cell clones 
whereby the INSC93S construct has randomly integrated into the genome. Gene 
expression data revealed differences in the expression level of the INSC93S transgene 
between the five transgenic founders (Figure 7). This outcome is also expected and 
results from effects of random integration. It is well known that expression levels are 
dependent on the number of integration sites as well as they are influenced by the 
integration site due to differences in chromatin remodeling of neighboring DNA 
(WOLF et al., 2000; RECILLAS-TARGA, 2006). We selected founders 9776 and 
9748 as they showed the highest expression levels of the INSC93S transgene and 
revealed IGT and reduced insulin secretion during an IVGTT (Figure 9). These results 
not only proved that the phenotype of INSC93S transgenic pigs is specifically triggered 
by the expression of the mutant insulin C93S rather than triggered by disruption of a 
functional gene (possibly caused by random integration of the INSC93S transgene) as 
they indicate that the effects of INSC93S expression in the development of a mild 
diabetic phenotype are dose-dependent. Moreover, we demonstrated that INSC93S is 
stable within the genome and is inherited by germline transmission to offspring. 
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Transgenic F1 offspring of 9776 (Figure 7) and 9748 (data not shown) showed the 
same INSC93S integration pattern and also a similar INSC93S/INS transcript ratio in the 
pancreas as their respective founder (Figure 7). These results argue in favor of one 
single integration site of the INSC93S transgene copies.  
INSC93S transgenic pigs develop a mild diabetic phenotype which is different from 
severe diabetes observed in humans carrying heterozygous INS mutations and different 
from the existing INS mutant animal models, including INSC94Y transgenic pigs 
(HERBACH et al., 2007; RENNER et al., 2013; LIU et al., 2015). In humans, 
dominant INS mutations cause a heterogeneous repertoire of severe forms of diabetes, 
including permanent neonatal diabetes, infancy-onset diabetes (i.e. diabetes diagnosed 
before 12 months of age), type 1b diabetes (i.e. non-autoimmune type 1 diabetes), 
maturity-onset diabetes of the young (MODY), and early-onset type 2 diabetes (STOY 
et al., 2007; COLOMBO et al., 2008; EDGHILL et al., 2008; MOLVEN et al., 2008; 
POLAK et al., 2008). The Munich Ins2C95S mouse model (corresponding mutation of 
the INSC93S transgenic pig), develops hyperglycemia and hypoinsulinemia from the 
fourth week of life (HERBACH et al., 2007). However, in contrast to humans and 
mouse models with mutant insulin genes, our pig model expresses the mutant INSC93S 
as a transgene, while the endogenous INS alleles are intact. Consequently, the 
phenotype of the founder animals was variable due to random transgene insertion and 
consequently different expression levels of INSC93S.  
Previously, transgenic pigs expressing the mutant insulin C94Y were generated, and 
one line developed permanent neonatal diabetes within the first week of life (RENNER 
et al., 2013). This INS mutation results in a proinsulin with one disrupted interchain 
disulfide bond (between the A- and B-chain of the insulin) (RENNER et al., 2013). In 
INSC93S transgenic pigs, the cysteine to serine exchange at position 93 leads to a 
disruption of an intra-A-chain disulfide bond of the proinsulin (Figure 3: Proinsulin 
amino acid sequence 
Proinsulin amino acid sequence composed of the A-chain, B-chain and the connecting 
peptide (C-peptide). The A- and B-chain of the insulin are connected by two interchain 
and one intrachain disulphide bonds. The arrow depicts the amino acid exchange 
cysteine to serine at position 93 (C93S) within the mutant insulin.  The differences in 
the phenotype between these two pig models could be attributed to (i) the expression 
level of the mutant INS (which was 20 % higher in INSC94Y transgenic pigs as 
compared to the INSC93S transgenic founder 9776 with the highest expression level of 
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the mutant insulin C93S  (RENNER et al., 2013) and (ii) possibly to differences in 
intracellular mechanisms to rescue different forms of misfolded insulin (LIU & 
KAUFMAN, 2003; LIU et al., 2005).  
The molecular mechanisms going along with the expression of the mutant insulin 
C93S were not explored in this study. However, it is well established that disruption 
of disulfide bonds causes misfolding of the mutant proinsulin (CHANG et al., 2003), 
blockage of its maturation process, and activation of ER stress response pathways, 
ultimately impairing β-cell function and resulting in β-cell death (IZUMI et al., 2003; 
ZUBER et al., 2004; LIU et al., 2005; PARK et al., 2010; RAJAN et al., 2010). 
Therefore, the translated misfolded proinsulin likely also cause a stress responses in 
the β-cells of INSC93S transgenic pigs (RENNER et al., 2013). Importantly, co-
expression of wt and mutant INS proteins in vitro interfered with secretion of the wt 
insulin, and this was caused by intracellular trapping of wt insulin by expression of 
insulin mutant forms (LIU et al., 2010). Since INSC93S transgenic pigs express both the 
mutant and the endogenous insulin one can speculate that the C93S mutation also 
interferes with wt insulin maturation and secretion by similar mechanisms.  
 INSC93S transgenic pigs develop a mild diabetic phenotype  
We have performed a detailed characterization of glucose tolerance and insulin 
secretion in INSC93S transgenic pigs of the F1 and F4 generation of founder 9776 by 
means of IVGTT and MMGTTs at four and seven months of age. First, we showed 
that, like in humans, glucose and insulin curve responses were influenced by the route 
of glucose administration (ABDUL-GHANI et al., 2006a). When glucose was 
administrated orally, glucose and insulin concentrations were gradually increased in 
wt pigs which reflected the slower rate of glucose absorption as compared with the 
abrupt rise in plasma glucose and insulin concentration following an intravenous 
glucose load. Interestingly, we observed that the insulin responsiveness of 4-month-
old INSC93S transgenic pigs during a MMGTT was better as during an IVGTT. 
Following an intravenous glucose load insulin secretion was reduced while during a 
MMGTT insulin response was only delayed but overall insulin secretion unaltered. 
(Figure 11, Figure 12, Figure 14). It is well known that glucose-induced insulin 
secretion is potentiated when glucose is given orally compared with intravenous 
administration. This is known as the incretin effect (ELRICK et al., 1964; MCINTYRE 
et al., 1964) and is mediated by the two incretin hormones, glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) reviewed in 
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(RENNER et al., 2016b). Both hormones are secreted by enteroendocrine cells in the 
intestine in response to nutrients (DRUCKER, 2006) and upon binding to their specific 
receptors in pancreatic β-cells they potentiate insulin secretion accounting for 20 to 60 
% of the total insulin response (NAUCK et al., 1986a; NAUCK et al., 1986b). Thus, 
these results indicate that although pancreatic β-cells have a functional defect due to 
expression of mutant insulin, they still respond, at least to some extent, to incretins. 
Secondly, we demonstrated that IGT in INSC93S transgenic pigs was aggravated at 
seven months of age as total insulin secretion was not only significantly reduced 
following during IVGTT (Figure 13 C and D) but also during MMGTT (Figure 15 C 
and D). Additionally, first phase (0-10 min) insulin secretion was absent in INSC93S 
transgenic pigs during IVGTT at seven months (Figure 12 C). 
Altered kinetics of insulin secretion are also described in human studies of individuals 
with both IFG and/or IGT (HANEFELD et al., 2003; FESTA et al., 2004; ABDUL-
GHANI et al., 2006b; ABDUL-GHANI et al., 2006a; FÆRCH et al., 2009). Isolated 
IFG in humans is characterized by a decrease in the first phase (first 10 min) insulin 
response during IVGTT and reduced early-phase (first 30 min) insulin secretion during 
OGTT while late-phase (60-120 min) insulin response is maintained normal. 
Individuals with IGT show normal fasting glucose levels but both early- and late-phase 
insulin secretion are accompanied with insulin secretion defects following OGTT. In 
this study, INSC93S transgenic pigs exhibited elevated FPG levels and IGT with 
impairment of both insulin secretion phases corresponding to those seen in pre-diabetic 
humans. In humans, the pathogenesis of IFG and IGT seems to be different and a 
combination of impaired insulin sensitivity with defects in insulin secretion 
(CARNEVALE SCHIANCA et al., 2003; NATHAN et al., 2007). Hepatic insulin 
resistance and insulin secretion defects in individuals with IFG accounts for excessive 
gluconeogenesis, resulting in elevated FPG and excessive early rise of glucose during 
first hour of OGTT (BOCK et al., 2007). However, maintenance of normal muscle 
insulin sensitivity and proper late phase insulin secretion enables plasma glucose levels 
in IFG to decline in late phase to near base line values at the end of OGTT. Contrary, 
individuals with IGT reveal muscle and hepatic insulin resistance as well as 
progressive defects in insulin secretion and thus resulting in elevated glucose levels 
directly after the glucose load and towards the end of OGTT (NATHAN et al., 2007; 
AOYAMA-SASABE et al., 2016). At both four and seven months of age, elevated 
stimulated glucose levels in INSC93S transgenic pigs were clearly associated with an 
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insulin secretion defect caused by the expression of the mutant insulin C93S. These 
results are consistent with reduced β-cell mass at 14 months of age (Figure 15). 
Elevated FPG levels in INSC93S transgenic pigs at four and seven months of age cannot 
be solely explained by defects in insulin secretion as fasting insulin levels in INSC93S 
transgenic pigs were only slightly lower than in wt controls (Figure 11 C, Figure 12 
C, Figure 14 C and Figure 15 C). Since reduced hepatic insulin sensitivity is often an 
acquired defect contributing for elevated fasting glucose levels in humans with IFG, 
hepatic insulin resistance might also play a role in IFG of INSC93S transgenic pigs. To 
address this hypothesis, hyperinsulinemic-euglycemic-clamps with a tracer would be 
required, and these will be done in future experiments. 
Finally, we observed different patterns of insulin secretion curves (monophasic curve 
and biphasic curve) that match decrease and increase of the respective glucose curves 
during MMGTTs (Figure 14 C and Figure 15 C). These distinct curve shapes are most 
likely related to the particular glucose challenge test type used in this study. MMGTTs 
are frequently used in pigs but differ from the standard OGTT protocols widely used 
in the clinic to diagnose human patients with IGT and diabetes mellitus (ADA, 2016). 
Unlike OGTTs in humans, where solely glucose is administrated orally, in MMGTTs, 
glucose plus a certain amount of pig food are mixed as to facilitate oral glucose 
consumption in pigs. As a result, glucose absorption may be influenced by the diet. In 
fact, fiber components are known to affect postprandial absorption of glucose giving 
rise to lower glucose and insulin concentrations, as well as to interfere with gastric 
emptying (JENKINS et al., 1978; TORSDOTTIR et al., 1989). In fact, as to counteract 
these disparities between tests, a recent study in 8-week-old pigs described a redefined 
OGTT method in pigs that resembles the OGTT in humans (MANELL et al., 2016). 
Nevertheless, it is important to point out that different glucose and insulin curve shapes 
have also been identified in humans during OGTTs (TSCHRITTER et al., 2003; 
NOLFE et al., 2012; HAYASHI et al., 2013). While, different insulin curve shape 
patterns strongly predict risk of developing diabetes (HAYASHI et al., 2013), others 
also indicate that individual characteristics such as gender and age are also associated 
to different oral glucose tolerance curve shapes (TSCHRITTER et al., 2003).   
In summary, expression of the mutant INSC93S in pigs triggers an impaired insulin 
response with development of mild hyperglycemia at fasting and reduced glucose 
tolerance following an oral and intravenous glucose challenge. This mild diabetic 
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phenotype in INSC93S transgenic pigs resembles some pre-diabetic phenotype forms in 
humans.  
 Females are slightly more glucose intolerant than male INSC93S 
transgenic pigs 
During IVGTTs performed at seven months of age, female INSC93S transgenic pigs 
showed a more pronounced IGT phenotype as compared to male INSC93S transgenic 
pigs (Figure 13 A, B, C and D). This was accompanied by reduced insulin secretion in 
females as compared to males. This result is contradictory to the results from the 
previously described Munich Ins2C95S mutant mouse model, in which female mice 
depict a significant milder disease phenotype compared to males (HERBACH et al., 
2007). In the Munich Ins2C95S mutant mouse model, this difference could be in part 
attributed to the protective effect of estrogen leading to a less pronounced phenotype 
in females (SCHUSTER, 2011). In fact, studies demonstrated that estrogens 
ameliorate oxidative stress and reduce apoptosis of pancreatic β-cells (LE MAY et al., 
2006), stimulate pancreatic β-cell secretion (ROPERO et al., 1999; BALHUIZEN et 
al., 2010), increase insulin sensitivity (LEE et al., 1999; GONZALEZ et al., 2001) and 
in ovariectomized Ins2C95S mutant females it improved glucose levels although it did 
not rescue β-cell loss (SCHUSTER, 2011) . Studies in the Göttingen Minipig revealed 
sex-related differences with females being more prone for the development of the 
metabolic syndrome and surprisingly revealed that males have higher concentrations 
of both testosterone but also estradiol (CHRISTOFFERSEN et al., 2007). Therefore, 
it could also be the case that in domestic pigs, males are more protected by effects of 
steroid hormones than females. This hypothesis is supported by the fact that this 
gender difference was observed in 7-month- but not in 4 months-old pigs. Seven 
months corresponds to the time when pigs reach sexual maturity.  
 Postprandial insulin secretion deficit is not sufficient to alter growth 
rate of INSC93S transgenic pigs 
Not surprising is the unaltered growth rate of INSC93S transgenic pigs compared with 
wt littermate controls. In humans, INS mutant carriers diagnosed with permanent 
neonatal diabetes are often born small for their gestational age as a consequence of the 
absence of insulin in utero, which acts as a growth factor and therefore promotes fetal 
growth (CAVE et al., 2000; POLAK & CAVE, 2007). In addition, insulin also impacts 
growth during postnatal life as shown by reduced growth rates in prepubertal children 
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with early onset of diabetes mellitus and poor glycemic control (TATTERSALL & 
PYKE, 1973; EDELSTEN et al., 1981; JACKSON, 1984). Transgenic pigs expressing 
the mutant insulin C94Y do not show reduced growth at birth but exhibit a 
progressively reduced growth rate from 2.5 month of age when not rescued with 
exogenous insulin, resulting in 40% reduced BW at 4.5 months of age (RENNER et 
al., 2013). In pigs the major postnatal growth rate occurs within the period from birth 
to six months of age (CORSON et al., 2008a). Contrary to INSC94Y transgenic pigs, 
INSC93S transgenic pigs do neither develop severe fasting hyperglycemia at birth, nor 
during juvenile ages and fasting plasma insulin levels are unaltered compared to 
controls. The insulin deficit in INSC93S transgenic pigs is manifested during 
postprandial periods when insulin secretion capacity is limited in these animals. 
Reduction of β-cell mass is also less pronounced in INSC93S transgenic pigs which are 
not dependent on insulin treatment. Thus, the degree of insulin deficiency is less 
marked in INSC93S than in INSC94Y transgenic pigs and although insulin secretion is 
impaired following a glucose challenge, the amount of insulin secreted seems to be 
enough to sustain normal growth. 
 Total β-cell volume is mildly reduced in INSC93S transgenic pigs 
We reported no differences in absolute and relative pancreas weight and this result is 
in line with unaltered growth rates in INSC93S transgenic pigs. When total β-cell volume 
was determined at 14 months of age in F1 offspring of founder 9776, a slight reduction 
(-22 %) of total β-cell volume was observed. Pancreatic β-cells secrete insulin in 
response to plasma glucose concentrations and thus, maintaining plasma glucose 
levels within a physiological range (NEWSHOLME et al., 2014). Loss of β-cell mass, 
is a feature of both type 1 and type 2 diabetes with reports showing 20 % - 65 % β-cell 
loss in type 2 diabetes (KLOPPEL et al., 1985; BUTLER et al., 2003; RAHIER et al., 
2008) and a substantial loss of 99 % in type 1 diabetes (MEIER et al., 2005). Evidence 
from human studies indicate that depletion of approximately 65 – 80 % of β-cell mass 
leads to insufficient insulin requirement and development of diabetes (KENDALL et 
al., 1990; MEIER et al., 2012). In a study involving eight NGT, 10 IGT and 11 type 2 
diabetic patients who underwent pancreatic surgery, it was demonstrated that β-cell 
area was directly correlated with glucose control in these patients, and the β-cell area 
reduction was 11.4 % in IGT (not significantly different from NGT controls) and 65 
% in type 2 diabetic patients (MEIER et al., 2009). However, insulin and C-peptide 
levels were not significantly decreased in these IGT patients compared with NGT 
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indicating that despite a small decrease of β-cell mass, β-cell function was still 
preserved in this particular group. In contrast, INSC93S transgenic pigs have an acquired 
β-cell function defect by the expression of the mutant INS. Hence, INSC93S transgenic 
pigs depict a model in which expression of the mutant INSC93S is the primary defect 
that alters β-cell function and leads to impairment of insulin secretion especially during 
stimulatory conditions. Under increased secretory demand, increased ER stress 
mediated by misfolding of the mutant INS can thus progressively trigger pancreatic β-
cell death with loss of pancreatic β-cell mass (IZUMI et al., 2003; ZUBER et al., 2004; 
LIU et al., 2005; PARK et al., 2010; RAJAN et al., 2010). This hypothesis is also 
supported by INSC94Y transgenic pigs as these animals develop severe hyperglycemia 
within the first week of age despite unaltered β-cell mass at that stage (RENNER et 
al., 2013). Another factor contributing to progressive reduction of β-cell mass is 
exposure to chronic hyperglycemia. In vitro studies demonstrated that hyperglycemic 
conditions induce β-cell stress by increasing cellular oxidative stress with increased 
production of reactive oxygen and nitrogen species (IHARA et al., 1999; FEDERICI 
et al., 2001; KAISER et al., 2003; MAEDLER et al., 2008). Although INSC93S 
transgenic pigs do not develop severe hyperglycemia, prolonged postprandial 
hyperglycemia levels caused by impaired glucose tolerance in INSC93S transgenic pigs 
could perpetuate a vicious cycle of increased secretory demand of β-cells and thus 
triggering more ER stress responses ultimately leading to some degree of β-cell 
apoptosis (IZUMI et al., 2003; HERBACH et al., 2007; LIU et al., 2007; LIU et al., 
2015). 
2. Metabolic changes of INSC93S transgenic pigs during 
pregnancy 
Next, we characterized the phenotype of INSC93S transgenic pigs during pregnancy. 
In healthy humans, normoglycemia is maintained during pregnancy despite several 
pregnancy-intrinsic-physiological changes that result in a “diabetogenic-like” 
phenotype characterized by (i) elevated postprandial glucose levels, (ii) increased 
whole body insulin resistance and (iii) increased circulating lipids. The hallmark for 
the development of diabetes during pregnancy is the inability to secrete enough 
endogenous insulin to meet the increased demand of insulin during pregnancy. 
Evidence from previous studies in wt pigs indicated that like in humans, pregnancy 
in pigs is a “diabetogenic-like” event where development of insulin resistance and 
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increased lipid mobilization at the end of gestation was observed (GEORGE et al., 
1978; SCHAEFER et al., 1991; PÈRE & ETIENNE, 2007). Therefore, we aimed to 
first characterize pregnancy changes in pigs and our hypothesis was that INSC93S 
transgenic pigs with IGT and mild elevated fasting glycaemia would not be able to 
cope with intrinsic metabolic stress of pregnancy and therefore develop a progressive 
diabetic state during pregnancy. 
 Pregnancy induced decrease in insulin sensitivity in pigs is not further 
impaired in INSC93S-p sows  
In vivo peripheral insulin sensitivity was measured in the third trimester by the gold-
standard technique, the hyperinsulinemic-euglycemic clamp (HIC). An insulin 
infusion rate of 1 mU/kg BW/min that was supposed to fully suppress hepatic insulin 
production was chosen (DEFRONZO et al., 1978; KOOPMANS et al., 2006). Blood 
glucose levels were clamped at a concentration of 75 mg/dl by a varying glucose 
infusion rate resembling a mean normal fasting blood glucose concentration for pigs. 
Glucose infusion rates were 35 % reduced in wt-p sows compared with wt-np controls 
(Figure 18 B and C), whereas GIR was not further reduced in INSC93S-p sows (Figure 
18 F and G). This indicates that, like in humans, insulin sensitivity is physiologically 
reduced during late pregnancy in wt pigs and that the expression of the mutant insulin 
C93S did not further impair insulin sensitivity (although a tendency towards reduced 
insulin sensitivity in tg pigs was observed). The finding of reduced insulin sensitivity 
during pregnancy is also supported by previous studies in the pig (GEORGE et al., 
1978; SCHAEFER et al., 1991; PÈRE et al., 2000; PÈRE & ETIENNE, 2007). The 
fact that insulin sensitivity is not further impaired in INSC93S-p sows is not surprising, 
since the molecular pathomechanism(s) of expression of the mutant INSC93S is 
reflected in defects in insulin secretion, rather than changes in peripheral insulin 
sensitivity. Women with GDM have defects in insulin sensitivity which may precede 
pregnancy (as part of either one or both genetic and environmental contribution) which 
is further impaired during pregnancy (RYAN et al., 1985; BUCHANAN et al., 1990; 
CATALANO et al., 1993; HOMKO et al., 2001). Nevertheless, GDM results from an 
endogenous insulin supply that is insufficient to meet the insulin demand 
(BUCHANAN & XIANG, 2005; BUCHANAN et al., 2007). An interesting point is 
why insulin resistance physiologically occurring during pregnancy combined with the 
intrinsic genetic defect in insulin secretion is not sufficient to trigger distinct 
hyperglycemia in INSC93S-p sows. One possible explanation is the difference in the 
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degree of physiological insulin resistance during pregnancy. In vivo studies measuring 
insulin sensitivity by means of HIC technique in GDM women indicate that insulin 
sensitivity is reduced by 50 % to 80 % compared with only 35 % in INSC93S-p sows 
(RYAN et al., 1985; BUCHANAN et al., 1990; CATALANO et al., 1991; 
CATALANO et al., 1992; CATALANO et al., 1993). Interestingly, GIRs reduced to 
a similar extent are reported among pregnant women with NGT were reported in our 
wt-p group. The molecular mechanisms underlying desensitization to insulin during 
pregnancy in humans are not fully understood. Nevertheless, data from human and 
murine studies, in healthy pregnancy and GDM, suggest that insulin resistance is 
multifactorial, involving a combination of increased maternal adiposity (with 
increased levels of adipokines and cytokines) in addition to desensitization effects of 
placental associated hormones (BARBOUR et al., 2007). Muscle and adipose tissue 
biopsy samples obtained from elective caesarian delivery reveal significant changes in 
IR activity, a decrease in total IRS1 protein concentrations and significantly decreased 
tyrosine phosphorylation of IR and IRS proteins that are aggravated in GDM 
(FRIEDMAN et al., 1999; SHAO et al., 2000; CATALANO et al., 2002; BARBOUR 
et al., 2011). As insulin resistance is physiologically developed in pigs, the same 
molecular mechanisms can be speculated and they can help for a deeper understanding 
on the development of insulin resistance during pregnancy. Understanding of these 
mechanisms can help to develop novel treatment strategies as to reduce insulin 
resistance in GDM patients.   
 Pregnancy is not enough to cause distinct hyperglycemia in INSC93S 
transgenic pigs 
Pregnancy did neither alter FPG in wt nor in INSC93S transgenic pigs. Unaltered FPG 
concentrations during gestation in wt pregnant sows are also reported by others and 
thus our results confirm these previous findings (AHERNE et al., 1969; REYNOLDS 
et al., 1985; DUEE et al., 1987; SIMOES NUNES et al., 1987; PÈRE et al., 2000; 
PÈRE & ETIENNE, 2007). In human pregnancy, different studies report a decrease in 
FPG throughout the course of gestation and, although the molecular mechanisms are 
not clear, it has been attributed to an increase in distribution volume with the 
establishment of pregnancy and to the growth of the fetal-placental unit in the last 
gestational phase (KALHAN et al., 1979; HADDEN & MCLAUGHLIN, 2009; 
ANGUEIRA et al., 2015). In the post-absorptive phase (fasting phase), the liver is the 
main contributor to FPG concentrations obtained by hepatic glucose production and 
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the rate of hepatic glucose production reflects the rate of glucose uptake (DEFRONZO 
et al., 1989). Metabolite turnover rates using tracer isotope dilution methods provide a 
better overview on metabolism as compared with point analysis concentrations which 
give only a static information for a parameter. Using these methods, it was shown that 
glucose turnover rate (appearance of glucose in the maternal circulation) during the 
post-absorptive phase was 16 % increased during pregnancy. This observation goes 
along with decreased glucose concentrations as a result of an increased distribution 
space (KALHAN et al., 1979). Insulin and glucagon are the two major glucoregulatory 
hormones that have a pivotal role in regulating hepatic glucose production (CAHILL 
et al., 1966; FELIG & WAHREN, 1971; UNGER, 1971; ALFORD et al., 1974). 
During prolonged fasting in humans, the decline in plasma insulin levels is a major 
hormone trigger to regulate hepatic glucose production and basal levels of glucagon 
are necessary to maintain hepatic glucose production. During pregnancy in humans, 
basal insulin levels rise, especially with progression of pregnancy (SPELLACY & 
GOETZ, 1963; BLEICHER et al., 1964; CATALANO et al., 1991; CATALANO et 
al., 1993) and reports indicate that glucagon levels do not differ from the non-pregnant 
state (LEBLANC et al., 1976). During our study, insulin levels were not monitored 
throughout pregnancy. However, we do have evidence that at the end of gestation basal 
insulin secretion was not different between the three groups (wt-np, wt-p and tg-p) 
(Figure 21 D). Therefore, it seems that regulation of basal glucose metabolism during 
pregnancy in pigs differs from humans. This hypothesis would also explain why FPG 
in INSC93S-p sows were not further impaired during pregnancy and remain unaltered 
compared with INSC93S-np controls. Women with GDM develop hyperglycemia that 
is a consequence of their inability to compensate for the increased insulin demand due 
to reduced insulin sensitivity compared to healthy pregnant women (RYAN et al., 
1985; CATALANO et al., 1993; HOMKO et al., 2001). We show that insulin 
resistance is not further impaired in INSC93S-p (Figure 18 E and F) and in fact, fasting 
plasma insulin concentrations during the third trimester indicate no additional insulin 
demand in the fasting state (Figure 21 D). Therefore, it could be expected that 
pregnancy-induced metabolic stress per se is not sufficient to provoke a distinct 
hyperglycemic state or overt diabetes in INSC93S transgenic sows. One possible way to 
achieve this would be the feeding of a high-energy-high-fat-diet. It was previously 
shown that the fat level in the diet fed to a sow during gestation is directly related to 
impaired glucose tolerance (VAN DER PEET-SCHWERING et al., 2004). Feeding a 
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high-fat diet combined to INSC93S transgenic pigs during pregnancy could be therefore 
a visible strategy in future studies to combine genetically and environmental factors to 
achieve a distinct diabetic state during pregnancy.  
 HGCs confirm reduced β-cell function in pregnant INSC93S transgenic 
sows  
In vivo β-cell function was evaluated by HGC, in which plasma glucose levels were 
acutely raised and sustained for 90 min at a hyperglycemic plateau of 300 mg/dL by 
variable glucose infusion rates. Because the same steady-state of hyperglycemia was 
achieved in INSC93S-p and wt-p sows (Figure 20 A), insulin response under maximal 
stimulatory conditions could be directly compared in the two groups. HGC confirmed 
that insulin secretion is severely impaired (- 71 %) in INSC93S transgenic compared 
with wt sows during pregnancy (Figure 20 B and C). This indicates that during 
pregnancy, under hyperglycemic conditions, INSC93S-p transgenic sows fail to 
compensate with an adequate insulin response but are able to react in a similar manner 
to an arginine bolus.  
 Pregnancy impaired glucose tolerance in wt-p sows and further 
aggravated glycemic control in INSC93S-p sows due to failure to 
compensate for an increased insulin demand 
In addition to HGC, β-cell function and glucose tolerance were evaluated during 
MMGTT, allowing us to determine glucose and insulin response in a closer natural 
scenario. We demonstrated that pregnancy induced a slight but significant degree of 
IGT in wt sows as shown by increased glycemia following meal ingestion that was 
sustained during one hour upon challenge (Figure 21 A). Wt-p sows secreted more 
insulin as to maintain normoglycemia despite a reduced insulin sensitivity compared 
to np controls (Figure 21 D and E). These results indicate that, like in humans, insulin 
is less effective for controlling circulating glucose in the later pregnancy stages which 
was also verified by others (SCHAEFER et al., 1991; PERE, 2001; PÈRE & 
ETIENNE, 2007), and altogether demonstrate that similar to healthy humans, wt-p 
pigs adapt as to keep sufficient glucose available for the fetuses during times of 
interrupted feeding (BUTTE, 2000; DI CIANNI et al., 2003). The molecular events 
underlying β-cell compensatory mechanisms (either by increasing β-cell function or 
mass) during pregnancy in humans have not been clarified. Rodent islets not only 
differ in terms of islet architecture compared with human and porcine islets 
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(CABRERA et al., 2006; KIM et al., 2009; STEINER et al., 2010), they also feature a 
much higher regeneration capacity (CHICK & LIKE, 1970; BONNER-WEIR et al., 
1983; FINEGOOD et al., 1995; MENGE et al., 2008). From the few studies analyzing 
β-cell mass adaption during pregnancy in humans (VAN ASSCHE et al., 1978; 
BUTLER et al., 2010) a much smaller increment in β-cell mass is seen as compared 
with the dramatic β-cell mass expansion in murine pregnancy, suggesting that human 
β-cells compensate insulin demand by increasing β-cell function of preexisting islets. 
How pigs regulate β-cell mass during pregnancy is not known. Future studies on this 
topic are important and may also shed light on human β-cell mass regulation during 
pregnancy.  
Furthermore, we showed that IGT was aggravated in mildly hyperglycemic, pregnant 
INSC93S transgenic sows compared to pregnant controls (Figure 21 A). The 
postprandial hyperglycemic burden observed in pregnant INSC93S transgenic sows is 
due to inappropriate compensatory insulin secretion capacity that can be explained by 
the expression of the mutant insulin C93S (Figure 21 D and F). The importance of β-
cell function in pregnancy is highlighted in in vitro stimulation studies using isolated 
islets of pregnant rats. It was demonstrated that islets isolated from pregnant rats 
(GREEN & TAYLOR, 1972) or isolated from rats with prolonged exposure to 
physiological progesterone and estrogen concentrations mimicking pregnancy 
conditions (COSTRINI & KALKHOFF, 1971), secreted more insulin to lower glucose 
levels compared with isolated female islets of non-pregnant controls. Increased insulin 
content and insulin secretion was also observed in glucose-stimulated pancreas tissue 
isolated from pregnant rats in comparison to pancreas from non-pregnant controls 
(MALAISSE et al., 1969). In addition, increased rates of proinsulin biosynthesis 
followed with increments in intracellular levels of adenylate cyclase and cyclic AMP 
were found in isolated islets of pregnant rats (BONE & TAYLOR, 1976), supporting 
evidence of increased needs in insulin production by β-cells during pregnancy. 
Because INSC93S transgenic animals show insulin secretion defects (Figure 21 D and 
F) and expression of mutant insulin C93S interferes with wt endogenous proinsulin 
secretion (LIU et al., 2010), these mechanisms may explain the deficit in response 
towards extra insulin demand during pregnancy in INSC93S transgenic sows.  
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 Wildtype neonates born to pre-diabetic INSC93S mothers reveal 
impaired glucose tolerance despite increased insulin secretion  
We demonstrated that wt offspring born to INSC93S mothers developed an insulin 
resistance phenotype at birth with elevated FPG and IGT (Figure 22 A and Figure 23). 
These results are the first to describe in vivo assessment of metabolic changes directly 
after birth in wt offspring in a large animal model of mild maternal hyperglycemia. 
The elevated FPG directly after birth in wt/tg might be a consequence of changes 
occurring during gestation in maternal glucose concentrations in utero, which were 
simultaneously transferred to the fetus. It is well documented that the fetus relies 
primarily on maternal glucose as energy source and that glucose is transferred to the 
fetus by a maternal-placental-fetal glucose gradient (KALHAN et al., 1979; 
KALHAN, 2004). Studies in humans demonstrate a linear relationship between 
maternal and fetal glucose concentrations, and this relationship is observed during 
euglycemia as well as hyperglycemia (WHALEY et al., 1966; TOBIN et al., 1969; 
FOWDEN et al., 1982; SOLTESZ et al., 1985; BOZZETTI et al., 1988; PERE, 1995). 
Like in humans the fetal pig uses glucose as the main substrate for development and 
growth (FORD et al., 1984; PERE, 1995) and elevation of maternal glucose correlates 
with increased fetal glucose levels in the umbilical vein of chronic catheterized fetuses 
(FOWDEN et al., 1982; PERE, 2001).  
Fetal/neonatal hyperinsulinemia is a feature of pregnancies complicated by diabetes, 
and is correlated with maternal degree of hyperglycemia (GROUP et al., 2008; 
METZGER et al., 2010). We could not demonstrate neonatal hyperinsulinemia as the 
large majority of insulin values obtained by RIA assay were below the detection limit 
of this assay. Nevertheless, we have some indication that wt/tg secreted more insulin 
at birth (time 0 min) (Figure 22 B) and showed that upon glucose challenge wt/tg 
piglets adapted with increased insulin secretion as compared to wt/wt offspring (Figure 
23 C and D), indicating that fetal pancreatic endocrine alterations must be present as 
to overcome elevated glucose levels in INSC93S mothers. In vitro evaluation of neonatal 
endocrine pancreas from neonates born to mothers with reduced carbohydrate 
tolerance showed an increased proportion of β-cells (VAN ASSCHE & GEPTS, 
1971). Islet hyperplasia and increased pancreatic insulin content is observed in the rat 
fetal pancreas exposed to a mild-hyperglycemia-induced-model of diabetes 
(KERVRAN et al., 1978; BIHOREAU et al., 1986a). We observed low insulin 
concentrations (less than 5 µU/mL) directly at birth in both groups and this is in line 
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with other reports of insulin measurements in the fetal pig during late gestation (103-
107 days) (FOWDEN et al., 1982; MARTIN et al., 1984; PERE, 1995). The low 
insulin levels are characteristic for pigs in comparison with sheep and cows (HOVE & 
BLOM, 1973; SIERS & TRENKLE, 1973; BASSETT, 1974) and may explain, in part, 
the scarce amount of fat in the piglet at birth compared with other neonates 
(WIDDOWSON, 1950). Human neonates are a remarkable exception in this respect 
as they show a greater fat mass to BW percentage at birth (12 %) compared with less 
than 2 % in piglets (LITTEN-BROWN et al., 2010). 
We report that wt/tg offspring secreted more insulin than wt/wt offspring although, 
glucose concentrations remain significantly higher during OGTT indicating IGT due 
to insulin resistance (Figure 23 A and C). There is a clear evidence that offspring 
prenatally exposed to an intrauterine hyperglycemic environment are at risk to develop 
IGT (SILVERMAN et al., 1995; PLAGEMANN et al., 1997) and type 2 diabetes with 
increasing age (DABELEA et al., 2000; LINDSAY et al., 2000). Whether this is also 
the case in a pre-diabetic maternal environment and the time window to which these 
alterations may occur is less explored. Two human studies addressed the presence of 
insulin resistance at birth as to understand if the same pathophysiological processes 
preceding onset of metabolic syndrome and diabetes in adults would be present before 
and at birth. The study from Dyer et al., performed in a Hispanic cohort of neonates (a 
population group at high risk to develop a metabolic syndrome) showed increased 
insulin resistance following a shortened-frequently-sampled-intravenous-glucose-
tolerance test in large-for-gestational-age term neonates born to mothers with and 
without gestational diabetes compared with that in poorly grown and normal for 
gestational age neonates between 24–48 h of birth (DYER et al., 2007). The study 
from Catalano et al in samples collected from the umbilical vein during delivery 
revealed increased insulin resistance measured by homeostasis model of insulin 
resistance in neonates of obese mothers with a positive correlation between fetal 
adiposity and insulin resistance (CATALANO et al., 2009). Our findings support and 
extend those suggesting that fetal metabolic programming can be influenced by 
chronically exposure to milder forms of maternal glycemia with metabolic alterations 
manifested at birth. We are aware that increased fetal/neonatal body fat mass and fetal 
overgrowth was not observed in this study. Although not significant, relative liver and 
heart weights tented to be higher in wt/tg compared with wt/wt (Table 9). It is worth 
to mention that excessive fetal growth (macrosomia) observed in human neonates 
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exposed to a diabetic intrauterine environment may be a difficult point to assess in 
pigs. This is due to intrinsic natural variation in BW at birth within the same litters 
(FOWDEN et al., 1997). The pig is a polytocous species in which littermates may 
compete for maternal glucose supply (FOWDEN et al., 1997). Therefore, although 
fetal glucose levels are determined primarily by the maternal nutritional state, in pigs, 
the relative placental mass of each fetus and the number of fetuses in the litter may 
influence fetal glucose consumption and fetal glucose concentrations 
(WIDDOWSON, 1971; COMLINE et al., 1979; FOWDEN et al., 1997). In addition, 
differences in placenta morphology among humans and pigs may impact placenta-
nutrient-transport-efficiency, and impact fetal growth. Contrary to the high 
invasive/permeable hemochorial placenta in humans, pigs have a less permeable type 
of placenta, the epitheliochorial (e.g. placenta transport of NEFAs is limited in the pig 
whereas it occurs in the human placenta) (LITTEN-BROWN et al., 2010).     
In our study, elevated insulin levels in wt/tg piglets following an oral glucose challenge 
suggest an excessive β-cell response with development of IGT. This is further 
supported in a prospective study where excess fetal insulin secretion in utero measured 
in the amniotic fluid strongly predicts IGT in childhood, and although most of the 
children with IGT were obese, IGT was not associated with macrosomia by multiple 
logistic analysis (SILVERMAN et al., 1995). In addition, a cross-section study 
involving pre-puberty children revealed that elevated maternal glucose levels during 
gestation are specifically associated with poor insulin sensitivity in the children and 
are positively associated with the offspring’s β-cell responsiveness independent of the 
children´s adiposity grade (BUSH et al., 2011). Interestingly, other studies reported 
lower insulin secretion among offspring of diabetic pregnancies (including GDM) 
(GAUTIER et al., 2001; SOBNGWI et al., 2003; SALBE et al., 2007; KELSTRUP et 
al., 2013). However, in these studies, insulin secretion was analyzed in the offspring 
at adulthood. Animal studies also support this evidence in which increased insulin 
secretion at younger ages follows reduced insulin secretion in adult life (BOLOKER 
et al., 2002; HOLEMANS et al., 2003). Reduced insulin secretion is also observed in 
adult rats which were exposed to mild-hyperglycemia (110 – 140 mg/dL) during 
gestation (GAUGUIER et al., 1991). Thus one could speculate that overstimulated β-
cell response in early life can precede reduced β-cell function and mediate β-cell 
decline and full blown diabetes in later life. The molecular mechanisms by which 
maternal hyperglycemia modulates the offspring´s insulin sensitivity and increased β-
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cell response are not fully understood. As previously mentioned, alterations in the 
morphology of the fetal pancreas with increased β-cell mass and insulin content were 
observed in animal and human studies (VAN ASSCHE & GEPTS, 1971; KERVRAN 
et al., 1978; BIHOREAU et al., 1986a). In addition, alterations in skeletal muscle 
glucose uptake resulting from decreased protein levels of GLUT1 and GLUT4 
transporters have been demonstrated in murine offspring exposed to diabetes in utero 
(BOLOKER et al., 2002). Together these data demonstrate that milder forms of 
hyperglycemia as seen in INSC93S tg sows can affect in utero programming of 
metabolic disorders which are already manifest early in the postnatal period. 
Combined environmental risk factors such as overnutrition in later life, triggering 
exaggerated β-cell response may contribute to exhaustion and decline of β-cell 
function. Ultimately, this may explain increased prevalence of metabolic syndrome 
and type 2 diabetes in the offspring of diabetic mothers.  
 
In addition, we demonstrate that maternal intrauterine exposure to mild hyperglycemia 
has effects on different clinical-chemical parameters in plasma of the offspring. During 
fetal development, mobilization of lipids for fat storage varies tremendously among 
humans and other mammalian species (JONES, 1982). In humans, body fat deposition 
occurs essentially in the last trimester of intrauterine life and accounts for 
approximately 16 % of neonatal body mass at birth (mainly in the form of white-
adipose tissue) (HERRERA & AMUSQUIVAR, 2000). In the pig white adipose tissue 
in significant amounts could not be detected macroscopically in 1-day-old piglets by 
our group and low body fat mass in neonatal piglets is also supported by others 
(WIDDOWSON, 1950; LITTEN-BROWN et al., 2010). These observations are 
consistent with the low levels of triglycerides, NEFAs and lipase observed at birth in 
both wt/tg and wt/wt piglets (Figure 24). We do observe a significant increase in total 
cholesterol which is consistent with increased levels of LDL and HDL in wt/tg 
compared with wt/wt piglets (Figure 24). We recognize that there is limited 
information of comparison of lipid profiles in neonates at term of GDM or diabetic 
mothers with offspring from healthy pregnancies. Lipeski et al. studied children (7-9 
years of age) 20 born to GDM and 22 born to healthy control mothers (matched for 
family history of diabetes and hypercholesterolemia) and reported no differences in 
mean of cholesterol, LDL and total HDL among GDM offspring and controls 
(LIPESKI et al., 1998). Others have determined the prevalence of metabolic markers 
V Discussion 104 
for the metabolic syndrome (including elevated FPG, triglycerides, HDL, waist 
circumference) in children (7-11 years of age) born to GDM and control mothers and 
indicated that 25 % of GDM offspring had at least one significantly changed metabolic 
marker with increased triglycerides being most prevalent (KEELY et al., 2008). In 
children dyslipidemia, obesity, insulin resistance and glucose intolerance are factors 
related to the metabolic syndrome and increase the risk for the development of diabetes 
and cardiovascular diseases in adulthood (BURNS et al.; SCHUBERT et al.; FRANKS 
et al., 2007; JUONALA et al., 2008). Our results suggest that mild maternal 
hyperglycemia had differential effects in lipid metabolism of wt/tg compared with 
controls at birth.  
Furthermore, we evaluated lactate and LDH metabolism as these substrates are directly 
related to glucose metabolism i.e. glucose is the major source of lactate and lactate is 
the major substrate for endogenous glucose production (ADEVA-ANDANY et al., 
2014). Patients with diabetes mellitus show severe alterations in intracellular 
metabolism of glucose in insulin-sensitive tissues including enhanced non-oxidative 
glycolysis with increased lactate production (THORBURN et al., 1990; DEL PRATO 
et al., 1993). In healthy subjects most of the glucose disposal during the postprandial 
period (43.5 %) is metabolized via the oxidative pathway (with pyruvate entering the 
mitochondria and follow the tricarboxylic cycle), 33 % is used for glycogen synthesis 
whereas 23.5 % follows the non-oxidative glycolysis pathway with formation of 
lactate (WOERLE et al., 2003). Although not significantly different, wt/tg piglets 
showed increased plasma lactate at two hours post oral glucose challenge compared 
with wt/wt (Figure 25 B). Consistently LDH was significantly higher two hours post 
oral glucose challenge in wt/tg (Figure 24 C). These results suggest that energy 
production during postprandial period in wt/tg is being enhanced through glycolysis 
via the non-oxidative pathway as compared to controls. Determination of levels of 
pyruvate dehydrogenase (PDH) as well as pyruvate would be necessary to confirm 
these preliminary observations. Interestingly, expression levels of genes involved in 
the mitochondrial oxidative pathway were found reduced in the skeletal muscle from 
patients with diabetes as compared to healthy controls (MOOTHA et al., 2003; PATTI 
et al., 2003), and reduced activity of PDH complex enzymes, are found reduced in 
vitro, in muscle of diabetic patients (ABBOT et al., 2005). Studies in chronic 
catheterized sows and fetal piglets indicate that lactate concentrations are increased in 
the fetal circulation compared to the maternal circulation (PERE, 1995, 2001) which 
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is also true for humans (GILFILLAN et al., 1985; BELL et al., 1989), sheep (BURD 
et al., 1975; CHAR & CREASY, 1976), guinea pigs (CARSTENSEN et al., 1982) and 
rats (SHAMBAUGH et al., 1977), suggesting that lactate is produced from glucose by 
the placenta. In pregnancies complicated by diabetes, excessive maternal blood 
glucose could facilitate overproduction of lactate in the placenta. Indeed, in vitro 
perfusion studies in human placentas from uncomplicated pregnancies perfused with 
gradually increased glucose concentrations indicate that the amount of lactate produce 
by the placenta is proportional to glucose concentration (HAUGUEL et al., 1986). 
Although, this is not confirmed in perfusion studies from placentas from GDM women 
(OSMOND et al., 2000). In contrast, another study indicates a 23% increase in the 
lactate concentration in the umbilical vein in GDM pregnancies (TARICCO et al., 
2009). We report no differences in basal levels of lactate at birth between wt/tg and 
wt/wt, suggesting that there were no differences in the placental lactate production 
among the two groups in this study.
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VI. CONCLUDING REMARKS AND PERSPECTIVES  
INSC93S transgenic pigs expressing the mutant insulin C93S develop mild diabetes 
characterized by elevated fasting glucose levels and impaired glucose tolerance. This 
phenotype is specific to the mutant INSC93S primarily causing a β-cell function defect, 
leading to impairment of insulin secretion, which is mostly evident under glucose-
stimulated conditions. Thus, INSC93S transgenic pigs represent a model of a subtle 
degree of diabetes which resembles a pronounced pre-diabetic state in humans. 
Pregnancy per se was not sufficient to further impair glycemic control in INSC93S 
transgenic pigs. However, it could be demonstrated that even milder degrees of 
hyperglycemia directly impact glucose control at birth in newborn wt piglets. Within 
this work two important questions were raised and should be addressed in future 
studies. First, which molecular events contributed to the metabolic alterations at birth 
in wt/tg piglets? Possible compensatory pancreatic alterations, such as increased β-cell 
mass or function was present in these animals. Development of insulin resistance was 
also suggested, and thus it would be important to determine if impairment of insulin 
signaling is present in peripheral tissues. Organ weight analysis showed that livers of 
wt/tg piglets tended to be heavier and clinical-chemical parameters also indicate 
increased liver metabolism. Therefore, it would be important to determine if the 
observed alterations in plasma metabolites are also associated with liver transcriptome 
changes of associated pathways. In addition, it would be mandatory to evaluate if in 
utero programming of metabolic disorders also persists during later developmental 
stages and if additional environmental risk factors, such as feeding a high-fat-high-
energy diet to the mothers, can contribute to the development of metabolic 
complications in this predisposed offspring. 
Other study applications that go beyond the maternal diabetes field can be explored in 
the INSC93S transgenic pigs. The pronounced pre-diabetic phenotype of these animals 
offers an excellent opportunity to identify possible early biomarkers related to β-cell 
dysfunction and compared to those found in the mild diabetic GIPRdn pig model with 
impaired incretin hormone function (RENNER et al., 2010). Moreover, high-fat diet 
manipulation in INSC93S transgenic pigs can possibly lead to an aggravated 
hyperglycemic phenotype and therefore, allowing to follow disease progression stages 
in a model integrating different comorbidities of diabetes (i.e. excessive weigh gain, 
dyslipidemia and possibly insulin resistance). 
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VII. SUMMARY  
Impaired glucose control in newborn piglets exposed to mild hyperglycemia in 
utero: study in a novel transgenic pig model for mild maternal diabetes  
 
Two types of maternal diabetes can be distinguished: preconceptional diabetes, i.e. 
preexisting type 1 or type 2 diabetes in the mother or gestational diabetes (GDM) with 
its first onset around the 24th week of pregnancy. Maternal diabetes negatively affects 
fetal development as well as triggers intrauterine programming of diseases in the 
offspring’s later life like obesity, impaired glucose tolerance and type 2 diabetes 
mellitus. The deleterious effects of maternal hyperglycemia on mother, fetus and early 
offspring are especially difficult to study in humans. Hence, experimental animal 
models are essential to better understand the consequences of maternal diabetes. The 
pig is an excellent animal model as pigs share many similarities with humans, e.g. fetal 
development is completed intrauterine in humans and pigs while mice are born at a 
more immature state. Until now, the majority of animal models for maternal diabetes 
was established in rodents by different approaches as pancreatectomy, chemical or 
dietary diabetes induction as well as genetic engineering. So far only few models with 
a milder phenotype similar to the mild hyperglycemic levels in mothers due to a tightly 
regulated glycemic control exist. Here, we established a novel porcine model of mild 
maternal diabetes using transgenic pigs expressing the mutant insulin C93S.  
INSC93S transgenic pigs were generated by somatic cell nuclear transfer and embryo 
transfer. Before pregnancy glucose control was investigated by an IVGTT and 
MMGTT and ß-cell mass was determined by quantitative-stereological analyses. For 
pregnancy studies, three INSC93S transgenic (tg) and nine wildtype (wt) sows were 
artificially inseminated with semen of the same wt boar while three wt sows served as 
non-pregnant controls. Fasting blood glucose was monitored weekly throughout 
pregnancy. Within the third trimester, hyperinsulinemic-euglycemic (HIC) and 
hyperglycemic clamps (HGC) as well as and mixed-meal glucose tolerance tests 
(MMGTT) were performed. At birth, wt piglets born to wt sows (wt/wt, n=18) and wt 
piglets born to tg sows (wt/tg, n=13) underwent an oral glucose tolerance test (OGTT) 
before first colostrum intake. Piglets were necropsied on day one for tissue collection. 
INSC93S transgenic pigs show mild impaired fasting glycaemia (IFG), impaired glucose 
tolerance (IGT) and insulin secretion as well as a slightly decreased in β-cell mass (-
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22 %). As observed in humans, insulin sensitivity was reduced in pregnant wt sows 
compared to non-pregnant wild-type controls within the third trimester. Insulin 
sensitivity of pregnant INSC93S transgenic sows was reduced to the same extent. β-cell 
function was severely reduced in INSC93S transgenic pregnant sows, displayed by 
reduced insulin secretion and glucose infusion rate during the HGC. In a MMGTT 
glucose tolerance was nearly, however not fully sustained in wt pregnant vs. non-
pregnant sows by increased insulin secretion, while INSC93S transgenic sows did not 
meet the increased insulin demand. Fasting hyperglycemia in INSC93S tg sows did not 
deteriorate further throughout pregnancy. Wildtype piglets born to wt sows (wt/wt) 
revealed unaltered birth and organ weights compared to wt piglets born to transgenic 
sows (wt/tg). However, glucose tolerance of wt/tg piglets was significantly reduced 
despite increased insulin secretion indicative of an insulin-resistant state. Additionally, 
wt/tg piglets showed significantly increased cholesterol as well as LDL and HDL 
levels. 
In summary, we established a novel transgenic pig model which reveals mild IFG and 
IGT representing a pronounced pre-diabetic state. As pigs and humans exhibit an 
insulin resistant-state during late pregnancy, INSC93S transgenic pigs seems to be a 
valuable model for the evaluation of consequences of mild maternal hyperglycemia on 
the offspring. Indeed, it was demonstrated in our study that mild maternal 
hyperglycemia resulted in impaired glucose tolerance despite increased insulin 
secretion as well as altered lipid metabolism in piglets at birth. This work can be further 
extended as to understand which molecular events contributed to the metabolic 
alterations at birth. Additionally, further studies will show if in utero programming of 
metabolic disorders also persists during later developmental stages, and how 
additional environmental risk-factors, such as feeding a high-fat-high-energy diet to 
the mothers affects their own as well as their offspring’s metabolism.  
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VIII. ZUSAMMENFASSUNG 
Verminderte Glukosetoleranz in neugeborenen Ferkeln infolge einer Exposition 
von maternaler Hyperglykämie: eine Studie in einem neuen transgenen 
Schweinemodell für geringgradigen maternalen Diabetes 
 
Bislang sind zwei Formen von maternalem Diabetes bekannt, einmal der 
präkonzeptionelle Diabetes, d.h. ein bereits vor der Schwangerschaft bestehender Typ 
1 oder Typ 2 Diabetes sowie Gestationsdiabetes, welcher zum ersten Mal zumeist um 
die 24. Gestationswoche auftritt. Maternaler Diabetes kann negative Auswirkungen 
auf die fötale Entwicklung sowie die Entwicklung von Krankheiten wie Adipositas, 
reduzierte Glukosetoleranz und Typ 2 Diabetes mellitus bei den Nachkommen 
begünstigen. Die Untersuchung der Auswirkungen des maternalen Diabetes auf die 
Mutter sowie frühe Entwicklungsstadien der Nachkommen ist beim Menschen kaum 
möglich. Aus diesem Grund sind aussagekräftige Tiermodelle von großer Bedeutung. 
Generell ist das Schwein ein exzellentes Tiermodell, da es sehr viele Ähnlichkeiten 
mit dem Menschen hat, die auch für die Untersuchung von Konsequenzen des 
maternalen Diabetes relevant sind. So wird beim Schwein wie auch beim Menschen 
die fötale Entwicklung intrauterin abgeschlossen, während Mäuse in einem unreiferen 
Stadium geboren werden. Bis heute wurden die meisten Tiermodelle zu diesem Thema 
im Nager mittels von Pankreatektomie, Diabetesinduktion durch chemische 
Substanzen wie Streptozotocin, durch spezielle Diäten oder mittels genetischer 
Modifikationen etabliert. Nur wenige der bislang etablierten Tiermodelle zeigen einen 
milden Phänotyp, d.h. nur eine geringgradige Hyperglykämie, die der Situation von in 
der Regel aufgrund einer engmaschigen Blutzuckerkontrolle gut eingestellten 
Schwangeren entspricht. Deshalb haben wir in der vorliegenden Studie ein neues 
Schweinemodell erstellt, welches eine milde Form von maternalem Diabetes zeigt. 
Transgene Schweine, die das mutierte Insulin C93S exprimieren, wurden mittels 
somatischen Kerntransfers mit anschließendem Embryotransfer erstellt. Zunächst 
wurde die Glukosehomöostase mittels eines intravenösen sowie eine „mixed-meal“ 
Glukosetoleranztests untersucht. Im Anschluss daran wurden weibliche Tiere mit 
Sperma desselben Ebers besamt und innerhalb des dritten Trimesters 
hyperinsulinämische-euglykämische Clamps (HIC), hyperglykämische Clamps 
(HGC) sowie ein „mixed-meal“ Glukosetoleranztest durchgeführt. Unmittelbar nach 
der Geburt und vor der ersten Kolostrumaufnahme wurden bei Ferkeln von nicht 
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transgenen Kontrollsauen (wt/wt, n=18) sowie bei nicht-transgenen Ferkeln von 
INSC93S transgenen Sauen orale Glukosetoleranztests durchgeführt. Zur 
Organprobenentnahme wurden die Ferkel am ersten Lebenstag euthanasiert und 
seziert. 
INSC93S transgene Schweine entwickeln geringgradig erhöhte gefastete 
Blutglukosespiegel, eine reduzierte Glukosetoleranz und Insulinsekretion sowie eine 
reduzierte ß-Zellmasse (-22%). Ähnlich wie beim Menschen zeigten 
Kontrollschweine eine reduzierte Insulinsensitivität im dritten Trimester, die bei 
INSC93S transgenen Schweinen ähnlich ausgeprägt war. Die ß-Zellfunktion während 
der Trächtigkeit war jedoch hochgradig gestört, was durch eine signifikant reduzierte 
Insulinsekretion sowie reduzierte Glukoseinfusion im HGC gezeigt werden konnte. Im 
MMGTT war die Glukosetoleranz bei trächtigen wt Sauen aufgrund einer signifikant 
erhöhten Insulinsekretion zur Kompensation der reduzierten Insulinsensitivität 
beinahe vollständig erhalten, während INSC93S transgene Sauen den erhöhten 
Insulinbedarf nicht vollständig kompensieren konnten und deshalb signifikant erhöhte 
Blutglukosespiegel zeigten. Die bereits bestehende gefastete Hyperglykämie bei 
INSC93S transgene Sauen verschlechterte sich während der Trächtigkeit jedoch nicht. 
Wt/wt Ferkel hatten ein unverändertes Geburtsgewicht sowie Organgewichte im 
Vergleich zu wt/tg Ferkeln. Die Glukosetoleranz von wt/tg Ferkeln war jedoch trotz 
einer signifikant erhöhten Insulinsekretion reduziert, was auf einen Status von 
Insulinresistenz hinweist. Zusätzlich zeigten wt/tg Ferkel signifikant erhöhte 
Plasmakonzentrationen von Gesamt-, sowie LDL- und HDL-Cholesterin. 
In der vorliegenden Studie wurde ein neues transgenes Schweinemodell, das 
geringgradig erhöhte, gefastete Blutglukosespiegel sowie eine reduzierte 
Glukosetoleranz entsprechend einem fortgeschrittenem prä-diabetischem Stadium 
entwickelt, etabliert und charakterisiert. Da Schweine wie auch Menschen während 
der späten Trächtigkeit eine Insulinresistenz entwickeln, erscheint das INSC93S 
transgene Schweinemodell als gut geeignetes Modell, um Auswirkungen des 
maternalen Diabetes auf die Mutter wie auch die Nachkommen untersuchen zu 
können. Es konnte in unserer Studie gezeigt werden, dass Nachkommen von 
prädiabetischen Sauen bereits bei Geburt Veränderungen des Glukosemetabolismus 
wie eine reduzierte Glukosetoleranz sowie Veränderungen im Lipidstoffwechsel 
zeigen. Zukünftige Studien müssen klären, ob diese Veränderungen fortbestehen, sich 
verschlimmern und zu einem Diabetes mellitus führen, welche molekularen 
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Mechanismen zugrunde liegen, und wie zusätzliche Faktoren, wie Adipositas, 
induziert durch das Füttern einer fettreichen-hochkalorischen Diät, sich auf Mütter und 
Nachkommen auswirken. 
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IX. INDEX OF ABBREVIATIONS 
ACTB ß actin 
ADA American Diabetes Association  
AUC area under the curve  
BMI body mass index 
BW body weight 
cDNA complementary deoxyribonucleic acid 
CETP cholesterol ester transfer protein  
CRL crown-rump length 
C-terminal carboxy-terminal 
CV coefficient of variance 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
DNA deoxyribonucleic acid  
dTTP deoxynucleotide triphosphate 
EDTA ethylenediaminetetraacetic acid 
FFA free fatty acids  
FPG fasting plasma glucose 
GDM gestational diabetes mellitus 
GLUT glucose transporter 
HAPO hyperglycemia and Adverse Pregnancy Outcomes 
HbA1c glycated hemoglobin  
HDL high-density lipoproteins 
HFD high fat diet 
HGC hyperglycemic clamp 
HIC hyperinsulinemic-euglycemic clamp 
hPGH human placental growth hormone 
hPL human placental lactogen  
IADPSG 
International Association of the Diabetes Pregnancy Study 
Groups  
IDF International Diabetes Federation  
IFG impaired fasting glucose 
IGT impaired glucose tolerance 
INS insulin  
IR insulin receptor tyrosine kinase 
IRS insulin-receptor substrate 
IVGTT intravenous glucose tolerance test 
LDL low density lipoproteins  
MMGTT mixed-meal glucose tolerance tests 
MODY maturity-onset diabetes of the young 
NEFA Non esterified fatty acids  
N-terminal amino-terminal 
OGTT oral glucose tolerance test 
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PCDM preconceptional diabetes mellitus  
PCR polymerase chain reaction 
PG postprandial glucose 
PI3K phosphatidylinositol 3-kinase  
PKB/AKT protein kinase B  
PKC atypical protein kinase C  
PRL prolactin 
RIA radioimmunoassay 
SCNT somatic cell nuclear transfer 
SEM standard error of means 
TNF-α tumor necrosis factor alpha 
UV ultraviolet 
VLDL very low density lipoproteins  
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